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Significance {#sec1}
============

**There is currently no effective treatment for diffuse intrinsic pontine gliomas (DIPGs), an aggressive type of brain tumor that occurs in children. To better understand how these tumors arise and progress, we analyzed mouse models carrying mutations that recapitulate those that occur in human DIPGs. Our studies uncovered an oncogenic mechanism of action of *Acvr1* mutations, involving an arrest in the maturation of a specific type of glial cells in the brain. Prompted by these findings, we demonstrated the therapeutic potential of a kinase inhibitor that can simultaneously block two oncogenic pathways driving DIPGs.**

Introduction {#sec2}
============

Among pediatric brain tumors, diffuse midline gliomas, which include diffuse intrinsic pontine gliomas (DIPGs), carry a particularly poor prognosis ([@bib33], [@bib34]). These tumors cannot be surgically resected, respond only transiently to radiation, and do not reliably respond to conventional chemotherapy or any targeted therapy tested to date ([@bib34]). The recent identification of recurrent genetic lesions in DIPGs provides an opportunity to dissect how these tumors develop, progress, and might be treated ([@bib48]). Around 85% of DIPGs carry missense mutations in a histone H3-encoding gene, most frequently *H3F3A* or *HIST1H3B*, in which methionine substitutes for lysine at position 27 (H3-K27M) ([@bib48], [@bib64], [@bib79]). The tumorigenic effects of K27M mutant histones involve dominant-negative inhibition of H3 K27 trimethylation over large portions of the genome ([@bib5], [@bib12], [@bib27], [@bib44], [@bib51], [@bib77]).

DIPG-associated *H3F3A*^*K27M*^ and *HIST1H3B*^*K27M*^ mutations co-occur with distinct recurrent genetic lesions ([@bib48]). In particular, approximately 80% of the *HIST1H3B*^*K27M*^ tumors contain mutations in *ACVR1* ([@bib7], [@bib20], [@bib70], [@bib80]), which encodes a bone morphogenetic protein (BMP) type I receptor. Around 55% of these tumors also carry mutations that hyperactivate phosphoinositide-3-kinase (PI3K) signaling, especially in *PIK3CA* ([@bib10], [@bib48]). DIPG-associated *ACVR1* mutations are known or predicted to confer gain of function ([@bib7], [@bib20], [@bib70], [@bib80]) by mechanisms that may include neomorphic ligand responsiveness ([@bib28], [@bib29]) or ligand-independent activation ([@bib54]). However, the mechanisms by which *ACVR1* mutations exert their oncogenic effects are unknown, and their delineation is crucial for the design of therapeutic strategies for *ACVR1*-mutant tumors.

Analyses of tumor evolution in DIPG patients have indicated that *H3F3A*, *HIST1H3B*, and *ACVR1* mutations occur very early during tumorigenesis, and are positively selected during tumor progression ([@bib31], [@bib57], [@bib75]). Additional lesions, such as *PIK3CA* mutations, arise later ([@bib57], [@bib75]). Because of their broad effects on epigenetics, H3-K27M mutations have been proposed to reprogram the fate of tumor-initiating glial cells to a more primitive state, or to arrest the differentiation of these cells ([@bib22], [@bib77]). Indeed, differentiation arrest is a hallmark event in the oncogenesis of many types of brain tumors ([@bib38], [@bib73]). Recent single-cell transcriptomic studies lend credence to the importance of this process in DIPGs, suggesting that these tumors are fueled by cells that are similar to oligodendrocyte precursors cells (OPCs) ([@bib19]). However, the underlying mechanisms have yet to be defined. Here, by generating and analyzing a conditional knockin mouse model of the DIPG-causing *ACVR1*^*G328V*^ mutation, we aimed to uncover how mutant ACVR1 drives tumorigenesis, and could be therapeutically targeted.

Results {#sec3}
=======

Expression of *Acvr1*^*G328V*^ in Murine Oligodendroglial Cells Causes Neurological Anomalies {#sec3.1}
---------------------------------------------------------------------------------------------

To model the DIPG-causing *Acvr1*^*G328V*^ mutation in mice, we engineered a conditional knockin allele, *Acvr1*^*floxG328V*^ ([Figure 1](#fig1){ref-type="fig"}A). We inserted a *loxP-*flanked transcriptional stop cassette in intron 7, upstream of a mutant exon 8 encoding the G328V substitution. Mice expressing the recombined *Acvr1*^*G328V*^ allele in the whole body died before or around birth, showing obvious developmental anomalies ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). To evaluate the effect of targeting the *Acvr1*^*G328V*^ mutation to a broad population of neuroglial progenitors, we crossed the *Acvr1*^*floxG328V*^ allele with the *Nestin-Cre* driver. However, the resulting animals showed no obvious abnormal phenotype. OLIG2-expressing cells in the ventral brainstem of juvenile mice and humans, most of which do not express Nestin, have been identified as candidate tumor-initiating cells in DIPG ([@bib46], [@bib53]). Therefore, we used *Olig2*^*Cre*^ to target the *Acvr1*^*G328V*^ mutation to OPCs. *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ mice were born at the expected Mendelian ratio, but some of them failed to gain normal body weight and died before weaning ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). By the third postnatal week, most surviving *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ animals developed overt neurological anomalies, often showing pronounced spasms when disrupted during rest, and moderate ataxia ([Figure 1](#fig1){ref-type="fig"}C; [Video S1](#mmc4){ref-type="supplementary-material"}).Figure 1*Acvr1*^*G328V*^ Causes Neurological Anomalies and Oligodendroglial Cell Expansion(A) Schematic of the *Acvr1*^*floxG328V*^ allele, and sequencing chromatogram from an *Acvr1*^*floxG328V/+*^ (G328V) mouse, showing the G→V substitution.(B) Survival curves of *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice and their littermates.(C) Snapshot of a video recording of a *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mouse experiencing spasms and motor anomalies.(D) Representative images of tdTomato-expressing cells in the brainstem of mice with the indicated genotypes, at postnatal day 7 (P7) and 21 (P21). Scale bars, 100 μm.(E) Quantification of the data shown in (D). Each dot represents an individual animal (two to four sections measured per mouse). Horizontal bars represent the mean. ^∗^p \< 0.05; assessed by unpaired t test.See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Video S1](#mmc4){ref-type="supplementary-material"}.

Video S1. Neurological Anomalies in *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ Mice, Related to Figure 1Video recordings showing typical neurological anomalies in three young *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice.

To verify whether the neurological defects observed in *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ mice were associated with abnormal function or impaired survival of oligodendroglial cells, we first examined the fate of cells carrying the *Acvr1*^*G328V*^ mutation by using the *ROSA26*^*LSL-tdTomato*^ reporter allele. Quantification of tdTomato^+^ cells in the ventral brainstem at postnatal days 7 (P7) and 21 revealed an approximately 2-fold increase in the number of lineage-traced cells in *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^;*ROSA26*^*LSL-tdTomato*^ animals compared with their littermate controls ([Figures 1](#fig1){ref-type="fig"}D and 1E). These results suggest that the *Acvr1*^*G328V*^ mutation favors oligodendroglial cell expansion, and that the neurological symptoms observed are likely due to the dysfunction of these cells.

*Acvr1*^*G328V*^ Induces Hyperactive BMP Signaling and Glial Cell Proliferation {#sec3.2}
-------------------------------------------------------------------------------

To investigate the molecular mechanisms underlying the oligodendroglial lineage cell expansion induced by *Acvr1*^*G328V*^, we generated primary glial cell cultures from neonatal *Acvr1*^*+/+*^ and *Acvr1*^*floxG328V/+*^ mouse brainstems ([Figure 2](#fig2){ref-type="fig"}A). Cells were transduced with adenoviruses encoding GFP (Ad-GFP) or GFP plus Cre (Ad-GFP-Cre). In *Acvr1*^*floxG328V/+*^ cells, Ad-GFP-Cre triggered recombination of the conditional allele and stimulated the phosphorylation of the canonical BMP signaling effector, SMAD1, but not of SMAD2 ([Figures 2](#fig2){ref-type="fig"}B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Ad-GFP-Cre-transduced *Acvr1*^*floxG328V/+*^ cells expressed higher mRNA and protein levels of the BMP target genes, *Id1*, *Id2*, and *Id3* ([Figure 2](#fig2){ref-type="fig"}C). Addition of the BMP ligand antagonist noggin decreased basal, but not *Acvr1*^*G328V*^-stimulated *Id1/2*/*3* expression ([Figure 2](#fig2){ref-type="fig"}D). Some activating *ACVR1* mutations have been shown to confer activin responsiveness to the receptor ([@bib28], [@bib29]). However, the activin antagonist follistatin, alone or combined with noggin, did not prevent *Id1/2/3* gene induction by *Acvr1*^*G328V*^ in glial cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These data suggest that the gain-of-function effects of the *Acvr1*^*G328V*^ mutation can be mediated independently of certain extracellular BMP ligands and activins. *Acvr1*^*G328V*^ stimulated moderate cell proliferation, as judged by the incorporation of 5-ethynyl-2′-deoxyuridine ([Figure 2](#fig2){ref-type="fig"}E). Accordingly, glial cells from *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ mice exhibited a growth advantage compared with those from their *Acvr1*^*+/+*^;*Olig2*^*Cre/+*^ littermates ([Figure S2](#mmc1){ref-type="supplementary-material"}D).Figure 2*Acvr1*^*G328V*^ Hyperactivates BMP Signaling and Stimulates Glial Cell Proliferation(A) Schematic depicting experiments in primary glial cells.(B) Western blot of lysates from *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ (floxGV) glial cell, transduced with Ad-GFP or Ad-GFP-Cre, probed with the indicated antibodies.(C) mRNA expression, measured by qPCR (left) and protein levels (right), assessed by western blot of Id1, Id2, and Id3, in *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ (floxGV) brainstem glial cells transduced with Ad-GFP or Ad-GFP-Cre. For qPCR, n = 3 experiments.(D) Expression of *Id1*, *Id2*, and *Id3*, measured by qPCR in *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ brainstem glial cells transduced with Ad-GFP or Ad-GFP-Cre, and treated or not with 100 ng/mL noggin. n = 4 experiments.(E) Percentage of 5-ethynyl-2′-deoxyuridine (EdU)-positive cells in GFP-negative and GFP-positive *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ glial cells transduced with Ad-GFP or Ad-GFP-Cre, and incubated with 10 μM EdU for 2 h. n = 3 experiments.(F) Normalized E2F-Luc reporter activity in *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ glial cells, transduced Ad-GFP-Cre, relative to reporter activity in cells transduced with Ad-GFP. n = 4 experiments.In all panels, mean + SEM is shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by repeated-measures ANOVA (C--E) with Sidak (C and D), or Dunnett (E) multiple comparisons test, or paired t test (F). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

The ID proteins can stimulate cell proliferation by inhibiting the expression of negative cell-cycle regulators or by interfering with the ability of the retinoblastoma-associated protein (Rb) to suppress the activity of E2F transcription factors ([@bib40]). Therefore, we measured the expression of E2F-dependent genes that drive the G1-to-S cell-cycle transition. *Ccna2* and *Cdc25a* were upregulated upon transduction of primary glial cells from *Acvr1*^*floxG328V/+*^, but not *Acvr1*^*+/+*^ pups, with Ad-GFP-Cre ([Figure S2](#mmc1){ref-type="supplementary-material"}E). A similar trend was observed for *Ccne1* ([Figure S2](#mmc1){ref-type="supplementary-material"}E). To verify whether the upregulation of these genes reflected enhanced E2F-dependent transcriptional activity, we transfected primary glial cells with an E2F-dependent luciferase reporter construct. Compared with *Acvr1*^*+/+*^ controls, *Acvr1*^*floxG328V/+*^ cells transduced with Ad-GFP-Cre showed greater reporter activity ([Figure 2](#fig2){ref-type="fig"}F). Levels of phosphorylated Rb, which were lower than in cells cultured in the presence of serum, remained unchanged across all conditions in these experiments ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Overall, these results suggest that *Acvr1*^*G328V*^-dependent induction of *Id1*/*2*/*3* expression drives cell-cycle proliferation by enhancing the activity of E2F transcription factors ([Figure S2](#mmc1){ref-type="supplementary-material"}G).

*Acvr1*^*G328V*^ Blocks Oligodendrocyte Differentiation and Upregulates PDGFRA {#sec3.3}
------------------------------------------------------------------------------

To more comprehensively delineate the molecular changes induced by the *Acvr1*^*G328V*^ mutation in the oligodendroglial lineage, we used RNA sequencing (RNA-seq) to profile the transcriptome of whole brainstems from postnatal day 7 *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ and *Acvr1*^*+/+*^*;Olig2*^*Cre/+*^ littermates. A total of 247 genes were differentially expressed between the genotypes, with a corrected p value \< 0.05 ([Table S1](#mmc2){ref-type="supplementary-material"}). Of these genes, 125 were upregulated, while 122 were downregulated. Several of the most downregulated genes in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ pups were markers of oligodendrocyte maturation, such as *Cnp1*, *Mobp*, *Mog*, and *Opalin* (*Tmem10*) ([Figure 3](#fig3){ref-type="fig"}A). We confirmed these results by qPCR for several genes ([Figure 3](#fig3){ref-type="fig"}B), and by immunostaining for CNP1 ([Figure 3](#fig3){ref-type="fig"}C). In the brainstems of *Acvr1*^*floxG328V/+*^;*Nestin-Cre* pups, expression of these genes was either normal or mildly altered, while *Id1* and *Id3* were upregulated, likely reflecting *Acvr1*^*G328V*^ activation in non-oligodendrocyte lineage cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Gene set enrichment analysis confirmed downregulation of the oligodendrocyte differentiation program in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ brainstems, as well as upregulation of BMP signaling ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C).Figure 3*Acvr1*^*G328V*^ Causes Differentiation Arrest of Oligodendroglial Lineage Cells(A) Heatmap depicting the relative expression of the top differentially expressed genes in the brainstem of postnatal day 7 (P7) pups.(B) Expression of selected genes, measured by qPCR, in the brainstems from P7 pups.(C) Immunofluorescence images showing CNP1 expression in the brainstem of mice at P21. Scale bars, 100 μm.(D) Representative PDGFRA immunohistochemistry images in brainstem sections from mice at P14. Scale bars, 100 μm.(E) Representative flow cytometry histograms, and quantification of the percentage of positive cells and mean fluorescence intensity, of PDGFRA antibody-stained brainstem cells from P7 pups. Each dot represents an individual animal; horizontal bars represent the mean.(F) Representative immunohistochemistry images showing PDGFRA protein expression in four *ACVR1* mutant DIPG samples. Scale bars, 50 μm.(G) Expression of selected genes, measured by qPCR, in the brainstems of P7 pups.(H) Expression of *Pdgfra* (left), and number of neurospheres generated, plotted as a function of the number of cells plated (right) in *Acvr1*^*+/+*^ neural stem cells transduced with lentiviruses encoding tdTomato, *Ascl1*, *Sox11*, or both *Ascl1* and *Sox11*. n = 5 (left) and 3 (right) experiments.In all panels, mean + SEM is shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by unpaired t test (B, E, and G), repeated-measures ANOVA with Tukey multiple comparisons tests (H). See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Notably, expression of *Pdgfra*, an OPC marker, was upregulated in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ brainstems ([Figure 3](#fig3){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). Although the *PDGFRA* gene is amplified or mutated in some pediatric high-grade gliomas and DIPGs, these alterations are very rarely seen in *ACVR1*-mutant tumors ([@bib48]). Thus, the transcriptional upregulation of *Pdgfra* induced by *Acvr1*^*G328*^ may serve as an alternative mechanism to gene amplification for enhancing PDGF signaling. Immunohistochemistry indicated a higher density of PDGFRA^+^ cells in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ brainstems ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). To confirm this phenotype, we used flow cytometry to measure PDGFRA protein on the surface of brainstem cells from *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ and *Acvr1*^*+/+*^*;Olig2*^*Cre/+*^ P7 littermates. The proportion of PDGFRA^+^ cells, as well as the relative intensity of the PDGFRA signal, were both increased in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ pups ([Figure 3](#fig3){ref-type="fig"}E). To assess the relevance of these observations for human tumors, we examined PDGFRA expression in histological sections from a panel of four *ACVR1* mutant DIPGs. In all cases, we observed prominent PDGFRA immunoreactivity in a proportion of cells, ranging from widespread (SU-DIPG-XXI, SU-DIPG-XXXVI) to more restricted (SU-DIPG-XXIII, SU-DIPG-XXXII) ([Figure 3](#fig3){ref-type="fig"}F). Such variability is expected from the heterogeneous nature of the tumors and tissue samples, and is consistent with the presence of a malignant cell population with oligodendroglial characteristics in most DIPGs ([@bib19]).

To assess whether gene expression changes induced by *Acvr1*^*G328V*^ extend to other *Acvr1* mutations, we analyzed *Acvr1*^*tnR206H/+*^*;Pdgfra-Cre* mice. In this model, the DIPG-causing *Acvr1*^*R206H*^ mutation is targeted to *Pdgfra*-expressing cells, which includes oligodendrocyte progenitors throughout the brain ([@bib9], [@bib42]). We confirmed *Pdgfra-Cre* activity in the brainstem ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Genes altered in the brainstems of *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice were similarly affected in *Acvr1*^*tnR206H/+*^*;Pdgfra-Cre* pups at P7, albeit more modestly ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Therefore, distinct activating *Acvr1* mutations have overlapping cellular effects.

To characterize the mechanisms whereby the *Acvr1*^*G328V*^ mutation impairs differentiation, we focused on transcription factors that control oligodendrocyte maturation. *Ascl1* and *Sox11* were among the top upregulated genes encoding transcription factors in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ P7 brainstems ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Table S1](#mmc2){ref-type="supplementary-material"}). Expression of both genes can be induced by BMP signaling in other contexts ([@bib23], [@bib66]). *Ascl1* was also upregulated in the brainstems of *Acvr1*^*tnR206H/+*^*;Pdgfra-Cre* and *Acvr1*^*floxG328V/+*^;*Nestin-Cre* mice, the latter being likely due to activation of *Acvr1*^*G328V*^ in the neuronal lineage ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3F). ASCL1 and SOX11 have been implicated in the control of oligodendroglial progenitor formation and maturation ([@bib4], [@bib8], [@bib16], [@bib56], [@bib68]). Ectopic expression of ASCL1 in adult glioblastoma cells induces features of neuronal maturation and inhibition of glial cell differentiation ([@bib59]). Accordingly, RNA-seq analyses suggested that the neuroblast marker *Dcx* was upregulated in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ P7 brainstems, although only a moderate trend was detected by qPCR ([Figure 3](#fig3){ref-type="fig"}G; [Table S1](#mmc2){ref-type="supplementary-material"}). Whereas expression of the neural stem cell marker *Sox2* was normal in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ pups, the neuroglial progenitor marker *Fabp7* was upregulated ([Figure 3](#fig3){ref-type="fig"}G). Expression levels of more mature neuronal markers were comparable between the genotypes ([Figure 3](#fig3){ref-type="fig"}G). In *Acvr1*^*+/+*^ neural stem cells, cultured in the presence of PDGF ligands, lentivirus-mediated ectopic expression of *Ascl1* and *Sox11*, but not either alone, increased the expression of *Pdgfra*, and enhanced neurosphere-forming ability ([Figure 3](#fig3){ref-type="fig"}H). Together, these results suggest that the *Acvr1*^*G328V*^ mutation blocks the differentiation of oligodendroglial lineage cells, and upregulates neuroglial progenitor markers.

An Endogenous *Hist1h3b*^*K27M*^ Mutation Cooperates with *Acvr1*^*G328V*^ to Induce the Expression of BMP Target Genes {#sec3.4}
-----------------------------------------------------------------------------------------------------------------------

The absence of tumors in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice suggested that additional genetic lesions are needed for gliomagenesis. Most *ACVR1*-mutant DIPGs carry *HIST1H3B*^*K27M*^ ([@bib48]). To model this mutation, we generated a mouse *Hist1h3b*^*K27M*^ knockin allele. *Hist1h3b*^*K27M/+*^ mice were viable and appeared to develop normally. Western blot analyses on postnatal day 7 brainstems revealed a global decrease in the level of H3 trimethylated at lysine 27 (H3-K27me3) in *Hist1h3b*^*K27M/+*^ mice ([Figure 4](#fig4){ref-type="fig"}A), in accordance with the known cellular effects of H3-K27M. However, this decrease was no longer evident in young adult *Hist1h3b*^*K27M/+*^ animals ([Figure 4](#fig4){ref-type="fig"}A), suggesting compensatory mechanisms or time-restricted effects. Addition of the *Hist1h3b*^*K27M*^ mutation in *Acvr1*^*floxG328V/+*^;*Olig2*^*Cre/+*^ mice did not substantially affect their partial early postnatal lethality and did not induce detectable brain tumors ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 4*Acvr1*^*G328V*^ and *Pik3cA*^*H1047R*^ Cooperate to Induce High-Grade Diffuse Gliomas in Mice(A) Left: representative western blots of brainstem tissue lysates from postnatal day 7 or adult mice, probed with the indicated antibodies. Right: quantification.(B) Expression of *Id1* measured by qPCR, in glial cells carrying the indicated combination of alleles ("floxGV": *Acvr1*^*floxG328V*^), transduced with Ad-GFP or Ad-GFP-Cre, and treated with 100 ng/mL noggin. n = 3 experiments.(C) Schematic of the *Acvr1*^*floxG328V*^, *Hist1h3b*^*K27M*^, *Pik3ca*^*floxH1047R*^, and *Olig2*^*Cre*^ knockin alleles, and survival curves of mice carrying the indicated combinations of alleles.(D) Representative H&E-stained brain tissue sections showing diffuse high-grade gliomas in three mice carrying the *Acvr1*^*floxG328V*^, *Pik3ca*^*floxH1047R*^, and *Olig2*^*Cre*^ alleles without (left), or with (middle and right) *Hist1h3b*^*K27M*^. Scale bars, 2.5 mm.(E) Representative immunohistochemistry images showing expression of the indicated proteins in tumors. Scale bars, 20 μm.(F) Expression of selected genes, measured by qPCR, in tumors and matched normal brain tissue from control littermates.(G) Representative H&E-stained sagittal brain tissue sections of NOD SCID gamma (NSG) mice xenografted in the brainstem (left) or midbrain (right) with cell lines derived from mouse tumors, at humane endpoint. Scale bars, 2.5 mm.In all panels, mean + SEM is shown.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by unpaired t tests (A and F), repeated-measures ANOVA with Tukey multiple comparisons tests (B), or Gehan-Breslow-Wilcoxon test (C). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Cells in primary brainstem glial cultures from *Hist1h3b*^*K27M/+*^ pups showed reduced global H3-K27me3 levels ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and proliferated slightly faster than their *Hist1h3b*^*+/+*^ counterparts ([Figure S4](#mmc1){ref-type="supplementary-material"}C). In these cells, induction of *Id1*/*2*/*3* gene expression by Ad-GFP-Cre transduction was highest in the presence of both the *Acvr1*^*floxG328V*^ and *Hist1h3b*^*K27M*^ alleles, with *Hist1h3b*^*K27M*^ having a small effect by itself ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}D). Accordingly, there was a higher proportion of proliferating cells in primary glial cultures carrying the *Acvr1*^*G328V*^ and/or the *Hist1h3b*^*K27M*^ mutations ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Concurrently, expression of *Acvr1*^*G328V*^ plus *Hist1h3b*^*K27M*^ additively stimulated E2F-dependent transcriptional activity ([Figure S4](#mmc1){ref-type="supplementary-material"}F). To assess whether this was associated with epigenetic priming induced by H3-K27M, we performed chromatin immunoprecipitation experiments. When compared with the repressed *Hoxd8* promoter, the BMP-responsive elements (BREs) of the *Id1* gene promoter ([@bib36]) showed relatively low H3-k27me3 occupancy in *Hist1h3b*^*+/+*^ glial cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Mutant H3-K27M was detected at the promoter of both genes, whereas SMAD1 was only bound to the BREs of *Id1* ([Figure S4](#mmc1){ref-type="supplementary-material"}G). In *Hist1h3b*^*K27M/+*^ cells, robust H3-K27me3 occupancy was maintained at the *Hoxd8* promoter, but reduced at the *Id1* promoter ([Figure S4](#mmc1){ref-type="supplementary-material"}G), consistent with previously described effects of H3-K27M on H3-K27me3 deposition at repressed versus active loci ([@bib27], [@bib52], [@bib61]). Together, these results suggest that epigenetic changes driven by endogenous *Hist1h3b*^*K27M*^ may facilitate BMP target gene induction and cell proliferation stimulated by *Acvr1*^*G328V*^ ([Figure S2](#mmc1){ref-type="supplementary-material"}G), but is not sufficient to drive tumor formation in our mouse model.

*Acvr1*^*G328V*^, *Hist1h3b*^*K27M*^, and *Pik3ca*^*H1047R*^ Cooperate to Induce High-Grade Diffuse Gliomas {#sec3.5}
-----------------------------------------------------------------------------------------------------------

In addition to *ACVR1* and *HIST1H3B*, several DIPGs harbor *PIK3CA* mutations ([@bib10], [@bib48]). To accurately model this combination, we generated *Acvr1*^*floxG328V/+*^*;Hist1h3b*^*K27M/+*^*;Pik3ca*^*floxH1047R/+*^*;Olig2*^*Cre/+*^ mice. Young animals carrying this genotype exhibited neurological symptoms that were comparable with those observed in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice. Most of the *Acvr1*^*floxG328V/+*^*;Hist1h3b*^*K27M/+*^*;Pik3ca*^*floxH1047R/+*^*;Olig2*^*Cre/+*^ mice succumbed to spontaneous brain tumors, with a median survival of 419 days ([Figure 4](#fig4){ref-type="fig"}C). Separating mice according to the various mutation combinations indicated that *Hist1h3b*^*K27M*^ is not required for the appearance of the tumors, but may accelerate their development and/or increase their incidence ([Figure 4](#fig4){ref-type="fig"}C). Importantly, tumors were never seen in *Olig2*^*Cre/+*^ mice carrying exclusively the *Acvr1*^*floxG328V*^ or *Pik3ca*^*floxH1047R*^ alleles, with or without *Hist1h3b*^*K27M*^. Histopathological analyses indicated that the tumors were invariably high-grade diffuse gliomas ([Figure 4](#fig4){ref-type="fig"}D). The tumors often infiltrated throughout many parts of the brain, particularly in the midbrain and thalamic regions, and more rarely involved the brainstem ([Figure S4](#mmc1){ref-type="supplementary-material"}H). The diffuse gliomas contained abundant mitotic figures and proliferating cells, as indicated by Ki67 immunohistochemistry ([Figure 4](#fig4){ref-type="fig"}E). The tumors also expressed PDGFRA and OLIG2 ([Figure 4](#fig4){ref-type="fig"}E), consistent with an oligodendroglial origin or phenotype, and contained a substantial population of cells that were positive for the glial/progenitor markers, Nestin and GFAP ([Figure 4](#fig4){ref-type="fig"}E). qPCR analyses confirmed upregulation of *Pdgfra*, *Olig2*, *Nestin*, and *Gfap* in gliomas, compared with matched normal brain tissue from control littermates ([Figure 4](#fig4){ref-type="fig"}F). The tumors also showed elevated expression of *Ascl1*, *Sox11*, and *Id1*, indicating that they preserve and amplify gene expression changes driven by *Acvr1*^*G328V*^ ([Figure 4](#fig4){ref-type="fig"}F). Cell lines derived from the tumors maintained elevated expression of these genes ([Figure S4](#mmc1){ref-type="supplementary-material"}I), and could generate high-grade diffuse gliomas when transplanted in the brains of NOD SCID gamma (NSG) mice ([Figure 4](#fig4){ref-type="fig"}G). Overall, these results indicate that the *Acvr1*^*G328V*^ and *Pik3ca*^*H1047R*^ mutations cooperate to induce high-grade diffuse gliomas when targeted to the *Olig2*-expressing lineage.

ASCL1 and SOX11 Regulate Human DIPG Cell Fitness and Tumorigenicity {#sec3.6}
-------------------------------------------------------------------

The above observations raised the possibility that ASCL1 and SOX11 mediate differentiation arrest and tumorigenesis in DIPGs. To evaluate the relevance of these factors in human DIPGs, we measured their expression in samples of normal human brain tissue and DIPG tumors. RNA-seq analyses revealed markedly increased expression of *ASCL1* and *SOX11* in DIPG samples compared with normal brain tissue, irrespective of the driver mutations ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A; [Table S2](#mmc1){ref-type="supplementary-material"}). Furthermore, expression of these two genes was strongly positively correlated ([Figures 5](#fig5){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). In *ACVR1* mutant DIPG cell lines, the BMP receptor inhibitor, LDN-193189, variably suppressed *ASCL1* and *SOX11* expression ([Figure S5](#mmc1){ref-type="supplementary-material"}B).Figure 5*ASCL1* and *SOX11* Inactivation Impairs DIPG Cell Fitness(A) *ACSCL1* and *SOX11* expression in *ACVR1*-mutant and *ACVR1*-wild-type DIPG tumors, or in normal brain tissue, calculated as fragments per kilobase million (FPKM).(B) Schematic depicting experiments measuring the relative fitness of tumor cells transduced with LentiCRISPRv2-GFP.(C) Relative percentage of GFP-positive cells over time in the indicated cell lines, transduced with lentiviruses encoding the indicated sgRNAs. n = 3 experiments.(D) Expression of *PDGFRA*, measured by qPCR, in GFP-positive SU-DIPG-XXXVI and HSJD-DIPG-007 cells transduced with lentiviruses encoding the indicated sgRNAs. n = 3 experiments.(E) Left: bright field and GFP fluorescence stereoscopic microscope images of an NSG mouse brain xenografted with LentiCRISPRv2-GFP-transduced SU-DIPG-XXXVI cells. Right: survival curves of NSG mice xenografted with 2 × 10^5^ SU-DIPG-XXXVI or HSJD-DIPG-007 cells transduced with lentiviruses encoding the indicated sgRNAs.(F) PDGFRA immunohistochemistry in HSJD-DIPG-007 tumors at endpoint. Scale bars, 50 μm.In all panels, mean + SEM is shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by linear regression and slope comparisons (C), repeated-measures ANOVA with Tukey multiple comparisons test (D), or Mantel-Cox test (E). See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

To test the functional roles of ASCL1 and SOX11 in DIPG tumor cells, we used CRISPR/Cas9-mediated gene editing to inactivate them individually and in combination in *ACVR1* mutant (SU-DIPG-IV, SU-DIPG-XXI, SU-DIPG-XXXVI, HSJD-DIPG-007) or wild-type (SU-DIPG-VI) cells. We used LentiCRISPRv2-GFP lentiviruses encoding Cas9, GFP, and sgRNAs targeting *ASCL1* or *SOX11*, and confirmed proper editing of the targeted loci in infected cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We then compared the relative fitness of CRISPR-edited cells with their non-edited neighbors by tracking the proportion of GFP-expressing cells over time ([Figure 5](#fig5){ref-type="fig"}B). In cultures transduced with lentiviruses encoding sgRNAs targeting *ASCL1*, *SOX11*, or both, but not a control sgRNA, the representation of GFP^+^ cells decreased with successive passages ([Figures 5](#fig5){ref-type="fig"}C, [S5](#mmc1){ref-type="supplementary-material"}D, and S5E).

Because our transcriptomic data indicated that *Ascl1* and *Sox11* upregulation in *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ mice occurred concurrently with oligodendrocyte differentiation arrest, we measured the effect of *ASCL1* and *SOX11* inactivation on *PDGFRA* expression in DIPG cells. Individual or combined CRISPR-mediated targeting of *ASCL1* and *SOX11* was associated with a reduction in *PDGFRA* expression in SU-DIPG-XXXVI and HSJD-DIPG-007 cells ([Figure 5](#fig5){ref-type="fig"}D). To assess the role of ASCL1 and SOX11 in regulating DIPG cell tumorigenicity *in vivo*, we xenografted CRISPR-edited SU-DIPG-XXXVI, or HSJD-DIPG-007, cells in the brainstem of newborn NSG mice. Compared with mice transplanted with cells transduced with LentiCRISPRv2-GFP encoding a control sgRNA, animals xenografted with *ASCL1* and *SOX11* gene-edited cells survived longer ([Figure 5](#fig5){ref-type="fig"}E), which was associated with reduced tumor PDGFRA expression at endpoint ([Figure 5](#fig5){ref-type="fig"}F). Here, these data demonstrate that ASCL1 and SOX11 control DIPG cell fitness and tumorigenicity.

Characterization of E6201 as an ACVR1 Inhibitor {#sec3.7}
-----------------------------------------------

Because differentiation-arrested cells frequently drive the growth of gliomas ([@bib38], [@bib73]), ACVR1 might be a valuable therapeutic target. E6201 is a covalent inhibitor of MEK1/2, which are effectors of PDGFRA signaling ([@bib25]). It is currently in a phase 1 clinical trial for CNS metastases in BRAF/MEK-mutant melanoma ([@bib2], [@bib72]). Using a cellular NanoBRET target engagement assay, we unexpectedly identified binding between E6201 and ACVR1 ([Figure S6](#mmc1){ref-type="supplementary-material"}A, half maximal inhibitory concentration \[IC~50~\] ≈ 0.25 μM). In cells, E6201 dose-dependently inhibited the activation of a BMP-responsive reporter (BRE-Luc) by exogenous BMP2, BMP6, or BMP9 ([Figures 6](#fig6){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}B). This effect was specific to the BMP pathway, as E6201 only poorly inhibited a transforming growth factor β (TGF-β)-dependent CAGA-Luc reporter ([Figure S6](#mmc1){ref-type="supplementary-material"}C, IC~50~ \> 10 μM). Consistently, E6201 blocked BMP ligand-stimulated phosphorylation of SMAD1 ([Figure 6](#fig6){ref-type="fig"}B). To identify which BMP receptors might be most effectively targeted by E6201, cells were transfected with constructs encoding constitutively active (ca-) versions of ACVR1, BMPR1A, or BMPR1B, all of which stimulated *BRE*-Luc activity and SMAD1 phosphorylation to comparable levels ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). E6201 dose-dependently inhibited BMP pathway activation induced by ca-ACVR1, whereas its effects on ca-BMPR1A and ca-BMPR1B were more modest ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). In addition, E6201 had a larger suppressive effect on pathway activation induced by mutant ACVR1 than by wild-type ACVR1 ([Figure S6](#mmc1){ref-type="supplementary-material"}F). These data suggested that E6201 preferentially inhibits ACVR1 among type I BMP receptors and is effective against mutant ACVR1.Figure 6Characterization of E6201 as an ACVR1 Inhibitor(A) Luciferase activity in lysates from C2C12 cells transfected with the BRE-Luc reporter and stimulated overnight with 25 ng/mL BMP2, 25 ng/mL BMP6, or 5 ng/mL BMP9, and the indicated concentrations of E6201. n = 3 experiments.(B) Western blot of lysates from C2C12 cell stimulated for 45 min with 25 ng/mL BMP2, 25 ng/mL BMP6, or 5 ng/mL BMP9, with the indicated concentrations for E6201 applied 45 min before BMP ligand addition, probed with the indicated antibodies.(C) X-ray crystal structure showing interactions of E6201 (pink) in the ATP-binding pocket of ACVR1 (brown). Bound waters are shown as blue spheres. Hydrogen bonds are indicated by green dashed lines. Parts of strands β1 and β2 are omitted for clarity.(D) Expression of *Id1*, measured by qPCR, in *Acvr1*^*+/+*^ or *Acvr1*^*floxG328V/+*^ glial cells transduced with Ad-GFP or Ad-GFP-Cre, and treated where indicated with 100 ng/mL noggin and/or 1 μM E6201. n = 3 experiments.In all panels, mean + SEM is shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by repeated-measures ANOVA with Tukey multiple comparisons tests. See also [Figure S6](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.

E6201 is an ATP-competitive inhibitor that targets MEK1 through covalent binding to Cys207 (PDB: [5HZE](pdb:5HZE){#intref0010}). In ACVR1, this cysteine residue is replaced by Ala353, preventing a comparable covalent interaction. Therefore, to obtain mechanistic insights into the inhibitory effect of E6201 on ACVR1, we solved the 1.5-Å structure of ACVR1 in complex with its interacting partner FKBP12 and E6201 by X-ray crystallography ([Figure 6](#fig6){ref-type="fig"}C; [Table S3](#mmc1){ref-type="supplementary-material"}). E6201 occupies the ATP-binding pocket of ACVR1 with a binding position similar to that in the equivalent MEK1 complex ([Figures S6](#mmc1){ref-type="supplementary-material"}G--S6J). Both MEK1 and ACVR1 form common hydrogen bonds to E6201 through the kinase hinge (for ACVR1, at His286) and catalytic loop regions (for ACVR1, at Lys340). The missing covalent linkage in ACVR1 is compensated for by a van der Waals interaction involving Ala353 as well as two additional hydrogen bonds: one involving the threonine gatekeeper residue (Thr283) and the other involving the catalytic lysine (Lys235), which is displaced in MEK1 by its distinct αC-out, DFG-out conformation. Further structures of BMPR1B suggest that this kinase favors a more collapsed conformation of the ATP-binding pocket that would disfavor the binding of E6201, potentially explaining the observed selectivity of E6201 for ACVR1 over other BMP receptors ([Figure S6](#mmc1){ref-type="supplementary-material"}K).

In primary brainstem glial cells, E6201 blunted basal and *Acvr1*^*G328V*^-stimulated *Id1* and *Id3*, but not *Id2*, gene expression ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}L). In the presence of the BMP ligand antagonist noggin, which by itself did not prevent *Acvr1*^*G328V*^-stimulated gene expression, E6201 completely blocked *Acvr1*^*G328V*^-induced *Id2* upregulation ([Figure S6](#mmc1){ref-type="supplementary-material"}L). Noggin and E6201 also had additive effects on *Id1* and *Id3* expression ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}L). Taken together, these data suggest that E6201 can inhibit hyperactive BMP signaling downstream of mutant ACVR1.

E6201 Inhibits DIPG Cell Growth and Delays Tumor Progression *In Vivo* {#sec3.8}
----------------------------------------------------------------------

Inhibition of both MEK1/2 and mutant ACVR1 suggested that E6201 may show activity against DIPG tumor cells. Indeed, E6201 dose dependently reduced the growth or viability of DIPG cell lines carrying *ACVR1* and *HIST1H3B* or *H3F3A* mutations (SU-DIPG-IV, SU-DIPG-XXI, SU-DIPG-XXXVI, HSJD-DIPG-007), while an *ACVR1*^*WT*^ cell line, SU-DIPG-VI, was less sensitive ([Figure 7](#fig7){ref-type="fig"}A). E6201 had a similar effect on tumor cells derived from spontaneous *Acvr1*^*G328V*^ mouse gliomas ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In *ACVR1* mutant DIPG cells, the effect of E6201 did not strictly correlate with that of the selective MEK inhibitor Trametinib, in agreement with the predicted distinct activities of the two compounds ([Figure 7](#fig7){ref-type="fig"}A). E6201 decreased endogenous p-SMAD1 and p-ERK1/2 levels, consistent with dual inhibition of ACVR1 and MEK1/2, whereas the ACVR1/BMPR1A/B inhibitor LDN-193189 affected only p-SMAD1, and Trametinib affected only p-ERK1/2 ([Figure 7](#fig7){ref-type="fig"}B). Accordingly, both E6201 and LDN-193189 robustly reduced *ID1* and *ID3* expression ([Figure 7](#fig7){ref-type="fig"}C), whereas *ID2* expression was largely unchanged, similar to the results in primary mouse glial cell cultures ([Figure 6](#fig6){ref-type="fig"}L). E6201 exerted its effects on DIPG cells at least in part by inducing apoptosis, unlike LDN-193189 ([Figure 7](#fig7){ref-type="fig"}D).Figure 7E6201 Impairs *ACVR1* Mutant DIPG Cell Viability and Tumorigenicity(A) Relative ATP-dependent luminescence activity in the indicated cell lines, exposed to increasing concentrations of E6201 (left), or Trametinib (middle). n = 3 experiments. Right: E6201 and Trametinib IC~50~ in *ACVR1* mutant cell lines.(B) Western blot of lysates from SU-DIPG-IV cells treated for 24 h with DMSO, 2 μM E6201, 1 μM LDN-193189, or 0.1 μM Trametinib, probed the indicated antibodies.(C) Expression of *ID1*, *ID2*, and *ID3*, measured by qPCR, in SU-DIPG-IV cells treated for 24 h with DMSO, 2 μM E6201, or 1 μM LDN-193189. n = 3 experiments.(D) Percentage of AnnexinV-positive cells in SU-DIPG-IV cells treated for 48 h with DMSO, 2 μM E6201, or 1 μM LDN-193189. n = 3 experiments.(E) Relative ATP-dependent luminescence activity in SU-DIPG-XXXVI (left) or HSJD-DIPG-007 (right) cells transduced with lentiviruses encoding the indicated sgRNAs, and exposed to increasing concentrations of E6201. Data were normalized to the vehicle-treated condition for each sgRNA. n = 3 experiments.(F) Experimental design and treatment protocol for assessment of E6201 in DIPG xenograft mouse models.(G) Survival curves of NSG mice xenografted at postnatal day 2 with 2 × 10^5^ SU-DIPG-XXXVI (left), or HSJD-DIPG-007 (right) cells, treated with E6201 or vehicle control (30% Captisol).In all panels, mean + SEM is shown. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; assessed by repeated-measures ANOVA with Tukey multiple comparisons tests (C and D), nonlinear regression analysis (E) or Mantel-Cox tests (G). See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

To assess the extent to which E6201 acts on DIPG cells by inhibiting ACVR1, we examined how the response to E6201 is affected by ablating the *ACVR1* gene. CRISPR/Cas9-mediated *ACVR1* gene inactivation impaired the growth or viability of SU-DIPG-XXXVI and HSJD-DIPG-007 cells ([Figure S7](#mmc1){ref-type="supplementary-material"}B), but also blunted the effect of E6201 ([Figure 7](#fig7){ref-type="fig"}E). These results are consistent with E6201 acting partly through inhibition of ACVR1 in DIPG cells. Given the strong association between *ACVR1* and *PIK3CA* mutations in DIPG, we evaluated the effect of combined treatment with E6201 and the brain-penetrant PI3K inhibitor Buparlisib ([@bib14]). By itself, Buparlisib had comparable dose-dependent inhibitory effects on cell growth or viability on all the DIPG cell lines tested ([Figure S7](#mmc1){ref-type="supplementary-material"}C). In SU-DIPG-XXXVI and HSJD-DIPG-007 cells, E6201 and Buparlisib had mostly additive effects, with modest synergy around the IC~30~--IC~50~ concentrations for both compounds ([Figure S7](#mmc1){ref-type="supplementary-material"}D).

E6201 shows good brain penetration, when administered peripherally in mice ([@bib24]). To further test the potential therapeutic utility of E6201, we examined its effect on survival in immuno-compromised mice xenografted with SU-DIPG-XXXVI or HSJD-DIPG-007 tumor cells. Mice were transplanted with 2 × 10^5^ tumor cells in the brainstem area at postnatal day 2, and injected intraperitoneally with 40 mg/kg E6201, or vehicle control, every other day, starting at postnatal day 15 ([Figure 7](#fig7){ref-type="fig"}F). In both xenograft models, E6201 prolonged survival ([Figure 7](#fig7){ref-type="fig"}G), demonstrating efficacy of the drug toward DIPG tumor cells *in vivo*.

Discussion {#sec4}
==========

By showing that mutant ACVR1 is sufficient to arrest the differentiation of oligodendroglial lineage cells ([Figure 8](#fig8){ref-type="fig"}), our results provide mechanistic explanations for the presence of *ACVR1* mutations among the earliest oncogenic events in a subset of DIPG, and for the recent discovery that DIPG malignant cells harbor features of OPCs ([@bib19]). By itself, the differentiation block induced by mutant ACVR1 does not appear to be sufficient to induce tumors. Indeed, patients carrying germline *ACVR1* mutations that overlap with those found in DIPG develop fibrodysplasia ossificans progressiva (FOP), but not DIPG ([@bib71]). Nevertheless, FOP patients can harbor brainstem lesions that resemble hamartomas ([@bib65]), and focal demyelinating lesions ([@bib35]). We observed that, similar to humans, the combination of *Acvr1*^*G328V*^, *Hist1h3b*^*K27M*^, and *Pik3ca*^*H1047R*^ led to the development of high-grade diffuse gliomas in mice ([Figure 8](#fig8){ref-type="fig"}). These spontaneous tumors spread over large areas of the midbrain and forebrain, but rarely involved the brainstem. In contrast, in humans, tumors harboring the cognate mutations preferentially arise in the pons ([@bib48]). Still, our results clearly demonstrated collaboration between *Acvr1*^*G328V*^ and *Pik3ca*^*H1047R*^ in driving tumorigenesis, faithfully recapitulating the synergy predicted by human genetic data. The localization of *Acvr1*^*G328V*^;*Pik3ca*^*H1047R*^ mutant tumors in our mouse model may have been influenced by the cell type targeted, although lineage tracing indicated that the *Olig2*^*Cre*^ allele is active in the ventral brainstem. Alternatively, interspecies biological differences may dictate anatomical preferences for tumor development.Figure 8Mutant *ACVR1* Arrests Glial Cell Differentiation to Drive TumorigenesisModel depicting the effects of *Acvr1*^*G328V*^, alone or together with *Hist1h3b*^*K27M*^, on the expression of ID1/2/3, ASCL1, SOX11, and PDGFRA, and downstream consequences on cellular proliferation and differentiation. PDGFRA induction downstream of ASCL1 and SOX11 may be direct or indirect (broken arrow). The effect of combined *Acvr1*^*G328V*^, *Hist1h3b*^*K27M*^, and *Pik3ca*^*H1047R*^ on tumor emergence and progression is illustrated.

In our mouse model, *Hist1h3b*^*K27M*^ was not strictly necessary for the emergence of tumors. Although some studies have shown a role for H3-K27M in glioma occurrence and progression in mice, a stringent requirement for mutant histones for tumorigenesis has not been consistently demonstrated ([@bib30], [@bib39], [@bib60]). Therefore, despite clear genetic and functional evidence supporting a driving role for H3-K27M mutations in the formation, progression, and maintenance of high-grade diffuse gliomas in humans ([@bib27], [@bib67]), whether and how this can be recapitulated in mice remains to be clarified. In our knockin model, an effect of *Hist1h3b*^*K27M*^ on brainstem H3-K27me3 levels was seen soon after birth, but was largely abolished in young adult mice. *Hist1h3b* encodes a replication-dependent histone, and therefore the effects of *Hist1h3b*^*K27M*^ may depend on cell division. The robust expansion of OPCs in the mouse brainstem that occurs after birth largely subsides by the end of the second postnatal week ([@bib46]), potentially explaining temporally restricted effects of the *Hist1h3b*^*K27M*^ mutation. In humans, the corresponding developmental "window of opportunity" may remain open for months or years, favoring tumor emergence. In our model, we observed very mild effects of *Hist1h3b*^*K27M*^ on gene expression and cell proliferation, consistent with observations reported in other *in vitro* contexts ([@bib39]). The mechanisms whereby H3-K27M drives tumorigenesis undoubtedly go beyond effects on cell proliferation ([@bib27], [@bib39]). Because cells with OPC characteristics are seen in both *ACVR1*-wild-type and *ACVR1*-mutant tumors ([@bib19]), H3-K27M mutations likely play a central role in differentiation arrest, as suggested previously ([@bib22], [@bib77]). Understanding how H3-K27M and *ACVR1* mutations cooperate to impose an OPC-like phenotype on DIPG cells is an important topic for future investigations.

Our study has uncovered several potential effectors of hyperactive signaling downstream of mutant ACVR1, including ID1/2/3, as well as the transcription factors ASCL1 and SOX11 ([Figure 8](#fig8){ref-type="fig"}). ID2 has previously been identified as a key mediator of glioblastoma cell "stemness" ([@bib41]). Furthermore, a subset of *ACVR1*-wild-type DIPG tumors harbors amplifications of the *ID2* gene ([@bib7], [@bib48]), positioning ID2 as a possible key effector of mutant ACVR1. Our identification of ASCL1 as a candidate mediator of *Acvr1*^*G328V*^-induced oligodendroglial lineage differentiation arrest was particularly intriguing. ASCL1 has well-described pro-neural functions ([@bib6]), and enhanced ASCL1 expression can impair adult glioblastoma tumorigenicity by promoting neuronal-like differentiation ([@bib59]). Our data show that increased *Ascl1* expression in *Acvr1*^*floxG328V*^;*Olig2*^*Cre*^ mice is associated with upregulation of certain neuroblast, but not mature neuronal, markers. Furthermore, ASCL1 is required for OPC formation ([@bib56]), is robustly downregulated during oligodendroglial cell maturation ([@bib8], [@bib16], [@bib68]), and is highly expressed in most DIPG cells ([@bib19]). Moreover, ectopic ASCL1 expression in adult glioblastoma inhibits some aspects of glial differentiation ([@bib59]). Therefore, ASCL1\'s function in gliomas likely depends on its expression levels and on the presence of other factors that modulate its activity, and could contribute to locking cells into a state characterized by properties of both neuronal and glial progenitors.

Understanding the molecular mechanisms of tumor initiation and progression is crucial to design therapeutic strategies that can efficiently inhibit or reverse tumor growth. Our data suggest that pharmacological targeting of mutant ACVR1 and/or processes related to OPC differentiation arrest, such as PDGFRA signaling, may be promising therapeutic strategies to suppress or reverse the fundamental processes that drive DIPGs. In this context, our characterization of E6201, a drug already known to target MEK1, as an ACVR1 inhibitor that can impair DIPG cell growth and viability, may be particularly interesting. Notably, E6201 can achieve good brain exposure in mice ([@bib24]), and we demonstrated here that it prolongs survival in DIPG brain xenograft models. In addition, E6201 has been well tolerated in phase I trials in human patients with solid tumors ([@bib72]). Our results support further exploration of E6201, and similar drugs that can target ACVR1 and/or PDGFRA signaling, as agents for the treatment of DIPGs.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**p-SMAD1/5/8Cell Signaling13820; RRID:[AB_2493181](nif-antibody:AB_2493181){#intref0015}p-SMAD1/5/8Peter ten Dijke's laboratoryN/ASMAD1Cell Signaling6944; RRID:[AB_10858882](nif-antibody:AB_10858882){#intref0020}p-SMAD2Cell Signaling3108; RRID:[AB_490941](nif-antibody:AB_490941){#intref0025}SMAD2Cell Signaling3103; RRID:[AB_490816](nif-antibody:AB_490816){#intref0030}Id1Santa Cruzsc-133104; RRID:[AB_2122863](nif-antibody:AB_2122863){#intref0035}Id2Santa Cruzsc-398104Id3Santa Cruzsc-56712; RRID:[AB_783921](nif-antibody:AB_783921){#intref0040}p-ERK1/2Cell Signaling9101; RRID:[AB_331646](nif-antibody:AB_331646){#intref0045}ERK1/2Cell Signaling9102; RRID:[AB_330744](nif-antibody:AB_330744){#intref0050}H3-K27me3Millipore07-449; RRID:[AB_310624](nif-antibody:AB_310624){#intref0055}Histone H3Abcamab10799; RRID:[AB_470239](nif-antibody:AB_470239){#intref0060}RbCell Signaling9309; RRID:[AB_2297442](nif-antibody:AB_2297442){#intref0065}p-RbCell Signaling9308; RRID:[AB_2141156](nif-antibody:AB_2141156){#intref0070}β-ActinSigmaA2066; RRID:[AB_476693](nif-antibody:AB_476693){#intref0075}α-TubulinSigmaT6199; RRID:[AB_477583](nif-antibody:AB_477583){#intref0080}PDGFRA (mouse)R&DAF1062; RRID:[AB_2236897](nif-antibody:AB_2236897){#intref0085}PDGFRA (human)Cell Signaling5241; RRID:[AB_10692773](nif-antibody:AB_10692773){#intref0090}CNPase (CNP1)Cell SignalingD83E10; RRID:[AB_10705455](nif-antibody:AB_10705455){#intref0095}Ki67Abcamab156956; RRID:[AB_2732028](nif-antibody:AB_2732028){#intref0100}GFAPDakoZ0334; RRID:[AB_10013382](nif-antibody:AB_10013382){#intref0105}OLIG2MilliporeMABN50; RRID:[AB_10807410](nif-antibody:AB_10807410){#intref0110}NestinBD Pharmigen556309; RRID:[AB_396354](nif-antibody:AB_396354){#intref0115}Biotinylated PDGFRA (mouse)Thermo Fisher13-1401-82; RRID:[AB_466607](nif-antibody:AB_466607){#intref0120}Anti-mouse-HRPAmersham/GE HealthcareNA9310; RRID:[AB_772193](nif-antibody:AB_772193){#intref0125}Anti-Rabbit-HRPAmersham/GE HealthcareNA934; RRID:[AB_772206](nif-antibody:AB_772206){#intref0130}Anti-rabbit-Alexa Fluor 680Thermo FisherA21109; RRID:[AB_2535758](nif-antibody:AB_2535758){#intref0135}Anti-mouse-IRDye 800CWLI-COR926-32210; RRID:[AB_621842](nif-antibody:AB_621842){#intref0140}Biotinylated rabbit anti-goatVector LaboratoriesBA-5000; RRID:[AB_2336126](nif-antibody:AB_2336126){#intref0145}Biotinylated rabbit anti-ratVector LaboratoriesBA-4001; RRID:[AB_10015300](nif-antibody:AB_10015300){#intref0150}Biotinylated goat anti-mouseVector LaboratoriesBA-9200; RRID:[AB_2336171](nif-antibody:AB_2336171){#intref0155}Biotinylated goat anti-rabbitVector LaboratoriesBA-1000; RRID:[AB_2313606](nif-antibody:AB_2313606){#intref0160}Cy5-conjugated donkey anti-rabbitJackson ImmunoResearch711-175-152; RRID:[AB_2340607](nif-antibody:AB_2340607){#intref0165}Streptavidin-FITCBD Biosciences554060; RRID:[AB_10053373](nif-antibody:AB_10053373){#intref0170}Ki67-APCThermo Fisher50-5698-82; RRID:[AB_2574235](nif-antibody:AB_2574235){#intref0175}**Bacterial and Virus Strains**Bacterial strain for cloning: NEB® 5-alphaNew England BioLabsC2987Adenovirus: Ad-GFPVector Biolabs1060Adenovirus: Ad-GFP-CreVector Biolabs1700**Biological Samples**Human DIPG tumor samples -- frozen blocksDr. Michelle Monje's laboratoryN/AHuman DIPG tumor samples and normal brain tissue - RNAseqDr. Cynthia Hawkin's laboratoryN/A**Chemicals, Peptides, and Recombinant Proteins**Neurobasal-A mediumThermo Fisher10888-022D-MEM/F-12Thermo Fisher11330-032HEPES solution for cell cultureThermo Fisher15630-080Sodium pyruvate solution for tissue cultureThermo Fisher11360-070MEM non-essential amino acidsThermo Fisher11140-050GlutaMAX-I supplementThermo Fisher35050-061Antibiotic/antimycotic solutionThermo Fisher15240-096TSM Base mediumWisent305-485-CLHanks\' Balanced Salt solutionWisent311-510-CLTrypLE Express Enzyme solutionThermo Fisher12604021Trypsin solutionWisent325-542-ELDMEM, high glucose, pyruvateThermo Fisher11995-065OPTI-MEMThermo Fisher31985062FuGENE HDPromegaE2311Fetal Bovine SerumWisent098150Fetal Bovine SerumThermo Fisher26140079Phosphate-buffered saline solutionWisent311-010Heparin for tissue cultureStemCell Technologies07980Lenti-X ConcentratorTakara631232B-27 supplement without vitamin AThermo Fisher12587-010Recombinant H-EGFShenandoah Biotech100-26Recombinant H-FGF-basic-154Shenandoah Biotech100-146Recombinant H-PDGF-AAShenandoah Biotech100-16Recombinant H-PDGF-BBShenandoah Biotech100-18Recombinant mouse nogginPreprotech250-38Recombinant mouse follistatinShenandoah Biotech200-24Recombinant Mouse BMP-2R&D355-BM-010Recombinant Mouse BMP-6R&D6325-BM-020Recombinant Mouse BMP-9R&D5566-BP-010Recombinant Mouse TGFβR&D7666-MB-005LDN-193189Sigma-AldrichSML0559TrametinibMedKoo Biosciences201458BuparlisibMedKoo Biosciences204690E6201Spirita OncologyN/AComplete, Mini, EDTA-free Protease Inhibitor CocktailRoche11836170001PhosSTOP phosphatase inhibitor tabletsRoche49068450014X Bolt LDS Sample BufferThermo FisherB000710X Bolt Sample Reducing AgentThermo FisherB0009Bolt 4-12% Bis-Tris Plus gelsThermo FisherNW04120BOXBioTrace NT nitrocellulose membrane for western blotPALL Life Sciences66485PVDF membrane for western blotRoche03010040001Immobilon PVDF membrane for western blotMilliporeIPFL0001020X Bolt MES SDS Running BufferThermo FisherB000220X Bolt Transfer BufferThermo FisherBT0006Luminata Crescendo Western HRP SubstrateMilliporeWBLUR0100Odyssey Blocking BufferLI-COR927-500002X Power SYBR Green PCR Sample MixThermo Fisher4368708Tracer-6908Promega<https://zenodo.org/record/1308267#.Xd1vja8VixA>Intracellular TE Nano-Glo Substrate/InhibitorPromegaN2160Lipofectamine 3000 Transfection ReagentThermo FisherL3000015DharmaFECT DuoThermo FisherT-2010-03Optimal Cutting Temperature (O.C.T.) compoundVWR25608-930EntellanSigma Aldrich1079600500Vectashield Antifade Mounting MediumVector LaboratoriesH-1000TBS LC-A /Mount Low Viscosity Mounting MediumCole-ParmerRK-48579-05Dynabeads AThermo Fisher10002DDynabeads GThermo Fisher10003DCytofix/Cytoperm BufferBD Biosciences554722Perm/Wash BufferBD Biosciences554723AnnexinV-FITCBioLegend6409067-AADBioLegend420404**Critical Commercial Assays**NucleoSpin Tissue KitMacherey-Nagel740952NucleoSpin Plasmid KitMacherey-Nagel740588NucleoSpin RNA Plus kitMacherey-Nagel740984NucleoSpin TriPrep kitMacherey-Nagel740966MinElute PCR purification kitQiagen28004TOPO-TA cloning kitThermo Fisher451641iScript cDNA synthesis kitBio-Rad1708891TruSeq Stranded Total RNA kitIllumina20020596PrestoBlue Cell Viability ReagentThermo FisherA13261ATPlite Luminescence Assay SystemPerkin Elmer6016947Dual-Luciferase Reporter Assay SystemPromegaE1910VECTASTAIN Elite ABC HRP KitVector LaboratoriesPK-6100Click-iT EdU Alexa Fluor 647 Flow Cytometry kitThermo FisherC10424**Deposited Data**RNA sequencing data, *Acvr1*^*+/+*^*;Olig2*^*Cre/+*^ and *Acvr1*^*floxG328V/+*^*;Olig2*^*Cre/+*^ postnatal day 7 brainstemsThis paperGEO: [GSE142776](ncbi-geo:GSE142776){#intref0185}X-ray crystal structure of the ACVR1-FKBP12 complex bound to E6201This paperPDB: [6I1S](pdb:6I1S){#intref0190}**Experimental Models: Cell Lines**SU-DIPG-IVDr. Michelle Monje's laboratoryRRID: CVCL_IT39SU-DIPG-VIDr. Michelle Monje's laboratoryRRID:CVCL_IT40SU-DIPG-XXIDr. Michelle Monje's laboratoryN/ASU-DIPG-XXXVIDr. Michelle Monje's laboratoryN/AHSJD-DIPG-007Dr. Ángel Montero Carcaboso's laboratoryRRID:CVCL_VU70HEK293TATCCRRID:CVCL_0063C2C12ATCCRRID:CVCL_0188293FTThermo FisherR70007**Experimental Models: Organisms/Strains**Mouse: *Acvr1*^*floxG328V*^This paperN/AMouse: *Hist1h3b*^*K27M*^This paperN/AMouse: *Pik3ca*^*floxH1047R*^ (FVB.129S6-*Gt(ROSA)26Sor*^*tm1(Pik3ca∗H1047R)Egan*^/J)The Jackson Laboratory016977; RRID:IMSR_JAX:016977Mouse: *Olig2*^*Cre*^ (B6.129-*Olig2*^*tm1.1(cre)Wdr*^/J)The Jackson Laboratory025567; RRID:MGI:4844109Mouse: B6.FVB-Tg(EIIa-cre)C5379Lmgd/JThe Jackson Laboratory003724; RRID:IMSR_JAX:003724Mouse: *ROSA26*^*LSL-tdTomato*^ (B6;129S6-*Gt(ROSA)26Sor*^*tm9(CAG-tdTomato)Hze*^/J)The Jackson Laboratory007905; RRID:IMSR_JAX:007905Mouse: *Acvr1*^*tnR206H*^[@bib42]N/AMouse: *Pdgfra-Cre* (C57BL/6-Tg(Pdgfra-cre)1Clc/J)The Jackson Laboratory013148; RRID:IMSR_JAX:013148Mouse: *R26*^*NG*^ (*Gt(ROSA)26Sor*^*tm1.2(CAG-EGFP)Glh*^)[@bib81]RRID:IMSR_JAX:012429Mouse : NSG NOD.Cg-*Prkdc*^*scid*^*Il2rg*^*tm1Wjl*^/SzJ)The Jackson Laboratory005557; RRID:IMSR_JAX:005557**Oligonucleotides**Oligonucleotides for cloningThis paperSee [Table S4](#mmc3){ref-type="supplementary-material"}Oligonucleotides for quantitative PCRThis paperSee [Table S4](#mmc3){ref-type="supplementary-material"}Oligonucleotides for sgRNA cloningThis paperSee [Table S4](#mmc3){ref-type="supplementary-material"}**Recombinant DNA**pKOII[@bib3]N/ALentiCRISPRv2GFPAddgene; Laboratory of Dr. David Feldser82416psPAX2Addgene; Laboratory of Dr. Didier Trono2260pMD2.GAddgene; Laboratory of Dr. Didier Trono12259ca-ACVR1 (human - Q207D)Laboratory of Dr. Kohei MiyazonoN/Aca-BMPR1A (human - Q233D)Laboratory of Dr. Kohei MiyazonoN/Aca-BMPR1B (mouse - Q203D)Laboratory of Dr. Kohei MiyazonoN/ApLEX306Addgene; Laboratory of Dr. David Root41391pLEX306-iCreLaboratory of Dr. Daniel SchramekN/ApLEX306-tdTomato-iCreLaboratory of Dr. Daniel SchramekN/ApLEX306-SOX11-iCreLaboratory of Dr. Daniel SchramekN/ApLEX306-ASCL1-iCreThis paperN/ANanoLuc Protein Fusion MCS VectorPromegaN1361Renilla Luciferase Control Reporter VectorPromegaE22616XE2F-LuciferaseLaboratory of Dr. Kristian HelinN/ABRE*-*LuciferaseLaboratory of Dr. Peter ten DijkeN/ACAGA*-*LuciferaseLaboratory of Dr. Petra KnausN/A**Software and Algorithms**Image JNational Institutes of Health<https://imagej.nih.gov/ij/>Image Studio Ver.5.0Li-CORN/AFASTQC v0.11.5Babraham Bioinformatics<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>MultiQC v0.8[@bib18]N/ASTAR aligner v2.5.2b[@bib15]N/ARSEM v1.3.0[@bib45]N/ADESeq2 R package v1.20.0[@bib47]N/ATrimmomatic v0.35[@bib82]N/AGenePatternBroad Institute<https://software.broadinstitute.org/cancer/software/genepattern/>SynergyFinder[@bib32]<https://synergyfinder.fimm.fi>MOSFLM[@bib43]N/AAIMLESS (CCP4 suite)[@bib78]N/APHASER[@bib50]N/APhenix Refine[@bib1]N/ACOOT[@bib17]N/ATLSMD[@bib58]N/AMolProbity[@bib13]N/AZEN pro imaging softwareZeissN/ANDP.view2 imaging softwareHamamatsuN/AFlowJo version 10Becton, Dickinson & CompanyN/APrism version 7.03GraphPadN/A

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tak Mak (<tmak@uhnresearch.ca>). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### *In Vivo* Animal Studies {#sec5.3.1}

For mouse studies, male and female animals were used. Depending on the experiment, mice were analyzed at specific postnatal days or in adulthood, as indicated in the text and in figure legends. Mice were on a mixed genetic background, and housed in temperature-controlled facilities under 12-hour light/12-hour dark conditions with access to food and water *ad libitum*. Littermates carrying appropriate genotype(s) were randomly assigned to experimental groups. All animal experiments were performed in accordance with institutional and federal guidelines, and approved by Animal Care Committees (Princess Margaret Cancer Centre: protocol \#985; Toronto Centre for Phenogenomics: protocol \#22-0272H).

### Human Studies {#sec5.3.2}

The RNA sequencing data from human tumor samples and normal brain tissue used in this paper were generated as part of a study being conducted at the Hospital for Sick Children (Toronto, Canada). Patients provided informed consent, and ethical approval was obtained from the Hospital for Sick Children Research Ethics Board (\#1000055059).

### Cell Lines and Primary Cultures {#sec5.3.3}

All cell lines and primary cultures were maintained in humidified cell culture incubators at 37°C under 5% CO~2~. HEK293T and C2C12 cells were obtained from ATCC. 293FT cells were purchased from Thermo Fisher. For mouse primary cell cultures, female and male littermates were used. Specific culture media varied depending on the cell lines or primary cell type, as described in the "[Method Details](#sec5.4){ref-type="sec"}" section. SU-DIPG-IV, SU-DIPG-VI, SU-DIPG-XXI, and SU-DIPG-XXXVI were a gift from Dr Michelle Monje (Stanford University, CA, USA). HSJD-DIPG-007 cells were a gift from Dr Ángel Montero Carcaboso (Hospital Sant Joan de Déu, Barcelona, Spain). Authentication of the DIPG cell lines was performed by Short Tandem Repeat profiling at The Centre for Applied Genomics (SickKids, Toronto, Canada).

### Studies Using Organisms as Source for Materials Used in Experiments {#sec5.3.4}

For X-ray crystallography studies, the ACVR1 kinase domain (residues 172--499) proteins were prepared from Sf9 insect cells, and the FKBP12 proteins were prepared from *E coli* strain BL21(DE3)R3-pRARE2.

Method Details {#sec5.4}
--------------

### Mice {#sec5.4.1}

#### Acvr1^floxG328V^ Allele {#sec5.4.1.1}

For the *Acvr1*^*floxG328V*^ allele, a targeting vector comprising the following elements was constructed: 1) an upstream homology arm comprising 3 kb of intron 7 of the *Acvr1* gene, amplified by PCR as an *HpaI*-*KpnI* fragment; 2) a *loxP*-flanked cassette comprising a minigene encoding exons 7-11 and the 3' untranslated region of *Acvr1* amplified by PCR as a *KnpI*-*NheI* fragment, as well as a *NheI*-*SalI* flanked transcriptional stop cassette comprising three copies of the SV40 polyadenylation sequence; 3) an *Frt*-flanked neomycin resistance cassette; 4) a downstream homology arm comprising 6 kb of the *Acvr1* gene, including exon 8, all of intron 8, exon 9, and a portion of intron 9, amplified by PCR as a *XmaI*-*NotI* fragment. A missense mutation converting glycine 328 to valine in exon 8 was introduced by site-directed mutagenesis. The targeting vector was assembled in the pKOII backbone ([@bib3]), downstream of a negative selection cassette encoding the diphtheria toxin A chain. The targeting vector was verified by sequencing (ACGT Corporation, Toronto, Canada) and linearized with *NotI* prior to electroporation in E14K embryonic stem cells.

#### Hist1h3b^K27M^ Allele {#sec5.4.1.2}

In mice, *Hist1h3b*, the orthologous gene to human *HIST1H3B*, is located within a histone gene cluster whose organization is perfectly conserved with humans ([@bib49]), although in mice it encodes H3.2, which differs from H3.1 by a single amino acid and can also be mutated in DIPGs. A targeting vector comprising the following elements was constructed: 1) an upstream homology arm comprising 4 kb of sequence upstream of the promoter of the single-exon *Hist1h3b* gene, amplified by PCR as a *KpnI*-*XhoI* fragment; 2) an *Frt-*flanked neomycin resistance cassette; 3) a downstream homology arm comprising 2.3 kb including the *Hist1h3b* gene promoter, coding sequence, and 3' region, amplified by PCR as a *BamHI*-*NotI* fragment. A missense mutation converting lysine 27 (proper nomenclature is in fact lysine 28) to methionine was introduced by site-directed mutagenesis. The targeting vector was assembled in the pKOII backbone([@bib3]), downstream of a negative selection cassette encoding the diphtheria toxin A chain. The targeting vector was verified by sequencing (ACGT Corporation, Toronto, Canada) and linearized with *NotI* prior to electroporation in E14K embryonic stem cells.

For both alleles, 125 μg of linearized targeting vector were electroporated in 30 million E14K ES cells. The electroporated cells were plated in a total of ten 10-cm cell culture dishes coated with 1% gelatin, and cultured in ES cell medium supplemented with 0.325 mg/mL G418. After 9 days of selection, 480 clones were picked and amplified in 96-wells plates. Proper targeting was verified by long-range PCR (Terra Taq, Clontech) on genomic DNA extracted from the ES cells, using a combination of primers in the selection cassette and outside of the homology arms. Presence of the *loxP* sites and point mutations was assessed by sequencing of the PCR products. Correctly targeted ES cells were microinjected in C57Bl/6 blastocysts, and transferred into the uterine horns of pseudopregnant females. Highly chimeric mice were backcrossed to C57Bl/6 mice, and germline transmission of the mutant alleles was tested by PCR screening of brown pups. Excision of the neomycin resistance cassette by breeding heterozygous *Acvr1*^*floxG328V*^ animals to "flp deleter" mice (*B6.129S4-Gt(ROSA)26Sor*^*tm1(FLP1)Dym/RainJ*^; Jax \#009086) resulted in sporadic leaky activation of the mutation, compromising the viability of a substantial proportion of the animals. Therefore, experiments were performed using mice that retained the selection cassette, which did not interfere with expression of the mutant *Acvr1* allele.

*Acvr1*^*tnR206H/+*^*;Pdgfra-Cre* mice ([@bib42]) and the *R26*^*NG*^ *Cre*-dependent GFP reporter allele ([@bib81]) have been described previously. *Olig2*^*Cre*^ (B6.129-Olig2^tm1.1(cre)Wdr^/J, Jax \#025567), *EIIa-Cre* (B6.FVB-Tg(EIIa-cre)C5379Lmgd/J, Jax \#003724), *Nestin-Cre* (B6.Cg-Tg(Nes-cre)1Kln/J, Jax \#003771), *Pik3ca*^*floxH1047R*^ (Gt(ROSA)26Sor^tm1\ (Pik3ca∗H1047R)Egan^, Jax \#016977) and *ROSA26*^*LSL-tdTomato*^ (B6.Cg-Gt(ROSA)26Sor^tm14(CAG-tdTomato)Hze^/J; Jax \#007914) mice were obtained from The Jackson Laboratory. NSG (NOD.Cg-*Prkdc*^*scid*^ *Il2rg*^*tm1Wjl*^/SzJ) mice were obtained from in-house breeding colonies at the Toronto Center for Phenogenomics.

### Patient-Derived DIPG Cell Lines {#sec5.4.2}

SU-DIPG-IV, SU-DIPG-VI, SU-DIPG-XXI, and SU-DIPG-XXXVI were obtained from the laboratory of Dr Michelle Monje (Stanford University, CA, USA). HSJD-DIPG-007 cells were a generous gift from Dr Ángel Montero Carcaboso (Hospital Sant Joan de Déu, Barcelona, Spain). Cells were cultured as described ([@bib26]). Cells were maintained in Tumor Stem Medium (TSM) (1:1 mixture of Neurobasal-A medium (Thermo Fisher \#10888-022) and D-MEM/F-12 (Thermo Fisher \#11330-032) supplemented with 10 mM HEPES (Thermo Fisher \#15630-080), 1 mM sodium pyruvate (Thermo Fisher \#11360-070), 0.1 mM MEM non-essential amino acids (Thermo Fisher \#11140-050), 1X GlutaMAX-I supplement (Thermo Fisher \#35050-061), 1X antibiotic/antimycotic (Thermo Fisher \#15240-096), 1X B-27 supplement without vitamin A (Thermo Fisher \#12587-010), 20 ng/mL recombinant H-EGF (Shenandoah Biotech \#100-26), 20 ng/mL recombinant H-FGF-basic-154 (Shenandoah Biotech \#100-146), 10 ng/mL recombinant H-PDGF-AA (Shenandoah Biotech \#100-16), 10 ng/mL recombinant H-PDGF-BB (Shenandoah Biotech \#100-18), and 2 ug/mL heparin (StemCell Technologies \#07980). TSM medium, containing the above components without B-27 and recombinant ligands, was also custom-formulated by Wisent (\#305-485-CL). For routine culture, cells were maintained in a humidified cell culture incubator at 37°C under 5% CO~2~. Cells were passaged and medium was changed every 7 days. Typically, 0.2 x 10^6^ SU-DIPG-IV cells, 2 x 10^6^ SU-DIPG-VI cells, 1 x 10^6^ SU-DIPG-XXI, 0.2 x 10^6^ SU-DIPG-XXXVI, and 0.4 x 10^6^ HSJD-DIPG-007 cells were plated in T-75 flasks to achieve confluence after 7 days of culture.

The DIPG cell lines were authenticated by Short Tandem Repeat profiling at The Centre for Applied Genomics (SickKids, Toronto, Canada). Furthermore, the presence and expression of the *ACVR1* mutations were confirmed by PCR amplification and sequencing of *ACVR1* coding regions from genomic DNA, and of the whole *ACVR1* coding sequence from cDNA prepared from the cell lines, using the primers listed in [Table S4](#mmc3){ref-type="supplementary-material"}.

### CRISPR/Cas9 Gene Editing in Patient-Derived DIPG Cells Lines {#sec5.4.3}

sgRNA-encoding oligonucleotides were designed using ZiFiT and CRISPR Design (MIT) and synthesized by Eurofins Genomics. Oligos were phosphorylated by incubating 100 nmol of the sense and antisense oligonucleotides in a 20 μl reaction mixture containing 1 mM ATP, 1X T4 reaction buffer, and 10 units T4 PNK (Promega) for 1 hour at 37°C. Oligos were then annealed by adding 70 μl H~2~O and 10 μl of 10X annealing buffer (100 mM Tris-HCL pH7.5, 10 mM EDTA, 500 mM NaCl, 20 mM MgCl~2~), and incubating at 95°C for 5 minutes, 85°C for 4 minutes, and ramping down the temperature by 0.5°C per minute from 80°C to 10°C in a PCR thermocycler. The annealed oligos were then cloned into the *Bsmb1* site of the LentiCRISPRv2GFP lentiviral vector ([@bib76]). Oligonucleotide sequences are provided in [Table S4](#mmc3){ref-type="supplementary-material"}.

For lentivirus production, 3 x 10^6^ HEK293FT cells were transfected with 8 μg lentiviral plasmid, 6 μg psPAX2 packaging plasmid, and 2 μg pMD2.G envelope plasmid (laboratory of Didier Trono) using Lipofectamine 3000 in 10-cm dishes. The next day, growth medium was replaced with 10mL fresh growth medium containing 20% FBS. 24 hours later, the medium was collected, spun at 300 x g to remove cells and debris and passed through a 22 μm MCE membrane syringe filter (Millipore). Lentiviral particles were precipitated by adding 1:3 parts Lenti-X Concentrator (Takara) and incubating overnight at 4°C. Precipitated viral particles were pelleted by centrifugation at 1500 x g for 45 minutes, and the pellet resuspended in 300 μl PBS. Viral particles were immediately used, or stored at -80°C.

For infection of DIPG cell lines, 1.5 x 10^5^ cells were transduced by mixing the appropriate lentiviral particles with 2 μg/mL polybrene in TSM culture medium, and incubated in a humidified cell culture incubator at 37°C under 5% CO~2~. In all experiments, a pool of two lentiviruses encoding distinct sgRNAs was used, to maximize target disruption in the non-clonal edited cell population. The amount of viral particles was balanced across conditions. The next day, cells were pelleted by 300 x g centrifugation, washed once in 1X HBSS, resuspended in TSM culture medium, and returned to the cell culture incubator until analysis.

To verify target editing, genomic DNA was extracted from GFP-positive sorted cells using the NucleoSpin Tissue kit (Macherey-Nagel \#740952), according to the manufacturer's instructions. The genomic regions comprising the targeted loci were amplified by PCR using primers listed in [Table S4](#mmc3){ref-type="supplementary-material"}, and cloned into the pCR2.1-TOPO vector using the TOPO-TA cloning kit (Thermo Fisher). Ligation products were transformed into DH5α bacteria (New England BioLabs) and plated on ampicillin-coated agar plates. Plasmid DNA was extracted from randomly selected bacterial colonies using the NucleoSpin Plasmid kit (Macherey-Nagel \#740588), and sequenced (ACGT Corporation, Toronto, Canada).

### Neural Stem Cell Culture and Derivation of Mouse Tumor Cell Lines {#sec5.4.4}

To derive tumor cell lines and normal neural stem cell cultures, the thalamic, midbrain and rostral hindbrain regions from postnatal day 2 pups (for normal neural stem cells), or brain tumors from mice at humane endpoint (for tumor cell lines), were dissected, cut in small pieces, and incubated at 37°C in 5 mL TrypLE reagent (Thermo Fisher) for 10 minutes. The tissue was dissociated by repeated pipetting, washed with 20 mL 1X HBSS, and filtered through a 100 μM nylon mesh. Cells were centrifuged at 300 x g for 5 minutes, resuspended in 2 mL TSM growth medium (described above), and plated in one well of a 6-wells cell culture plate. Cells were maintained in a humidified cell culture incubator at 37°C under 5% CO~2~, typically reaching confluence after 5-7 days. At that point, cells were routinely passaged and expanded as described for DIPG cell lines. All experiments with normal neural stem cells were performed on cells between the first and fourth passage.

### Lentivirus Transduction of Neural Stem Cells, and Neurosphere-Forming Assays {#sec5.4.5}

For ectopic expression experiments, the pLEX306 vector, a gift from David Root (Addgene plasmid \# 41391) was modified to encode Cre recombinase instead of a puromycin resistance cassette, by conventional cloning using *KpnI* and *HpaI*, generating pLEX306-iCre. The coding sequences for tdTomato or mouse SOX11 were inserted in-frame with a C-terminal V5 tag into pLEX306-iCre using gateway cloning. For ASCL1, the full-length coding sequence of the mouse *Ascl1* gene was amplified from cDNA generated from total brain RNA, using the primers listed in [Table S4](#mmc3){ref-type="supplementary-material"}, and cloned between the *NheI* and *EcoRV* restriction sites of pLEX306-iCre. Lentiviral particles were generated, and neural stem cells were processed for lentiviral transduction, as described above for DIPG cell lines.

For neurosphere-forming assays, 0, 10, 20, 100, 200 or 1000 cells were plated in individual wells in ultra-low attachment polystyrene 96-wells plates (Corning) (6 replicate wells per condition). The number of neurospheres in each well was counted 7 days after plating.

### Primary Brainstem Glial Cell Culture and Adenovirus Infection {#sec5.4.6}

Primary brainstem glial cells were prepared by adapting previously published procedure developed for cortical cultures ([@bib62]). Brainstems were dissected from postnatal day 3 pups under a Leica MZ75 dissection microscope in cold 1X HBSS. The brainstem tissue was chopped in small pieces, and transferred to a 50-mL conical tube containing 1X HBSS supplemented with 0.05% Trypsin. The tissue was incubated in a 37°C water bath for 30 minutes, with occasional vortexing, and centrifuged at 300 x g. The liquid was aspirated, and the tissue resuspended in 10mL warm growth medium (DMEM supplemented with 1X antibiotic/antimycotic and 10% heat-inactivated fetal bovine serum). A single-cell suspension was prepared by pipetting up-and-down several times, followed by passing through a 100 μm nylon mesh. Additional growth medium was added to a final volume of 20 mL, and the cell suspension plated in a T-75 flask coated with 50ug/mL poly-D-lysine. Cells were maintained in a humidified cell culture incubator at 37°C under 5% CO~2~. 9 days after plating (DIV9), confluent cells were split for experiments. Medium was aspirated, cells were washed with 1X phosphate-buffered saline (PBS), and dissociated in 0.05% trypsin. For adenovirus infection, 0.75 x 10^6^ cells were plated in 10-cm dishes. The next day, 20 x 10^6^ PFU of the appropriate adenoviruses (Ad-GFP; Vector Biolabs \#1060, or Ad-GFP-Cre, Vector Biolabs \#1700) were added to the plates in 8mL growth medium. 24 hours later, the viral transduction medium was replaced with 8 mL fresh growth medium. The following day, cells were washed with PBS and incubated with serum-free medium supplemented with drugs or recombinant ligands as indicated. For gene expression and protein analyses, cells were collected in trypsin 20 hours later.

### C2C12 and HEK-293 Cells Culture {#sec5.4.7}

C2C12 and KEK-293 cells were maintained in DMEM medium (Gibco, Thermo Fisher) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher), and penicillin/ streptomycin (Thermo Fisher).

### Drugs {#sec5.4.8}

E6201 was obtained from Spirita Oncology. LDN-193189 was purchased from Sigma-Aldrich. Trametinib and Buparlisib were purchased from MedKoo Biosciences. Recombinant mouse noggin was from Preprotech, and mouse follistatin was from Shenandoah Biotechnology. For *in vivo* administration, E6201 was supplied by Spirita Oncology in lyophilized form, pre-weighted in sealed vials, and reconstituted with sterile water for injection, yielding a final concentration of 6 mg/mL in 30% Captisol. Vehicle control solution was prepared by dissolving Captisol in sterile water for injection. The drug was dissolved freshly before each injection. The drug was administered by intraperitoneal injections, using 27 Gauge needles fitted to 0.5 mL syringes.

### Xenograft Models {#sec5.4.9}

DIPG tumor xenografts were performed following previously-described guidelines ([@bib26]). 2 x 10^5^ cells, in a volume of 2 μL phosphate-buffered saline, were injected in the brainstem (3 mm posterior to lambda suture; 3 mm deep) of cold-anesthetized, postnatal day 2 NSG mice, using a 27 Gauge Hamilton syringe fitted to a custom stereotactic apparatus. For xenograft of mouse-derived cell lines, injections were targeted to the midbrain (thalamus) or hindbrain (brainstem) regions.

### RNA and Protein Extraction {#sec5.4.10}

For cultured cells, RNA was extracted using the NucleoSpin RNA Plus kit (Macherey-Nagel \#740984). In some experiments, DNA, RNA and proteins were extracted using the NucleoSpin TriPrep kit (Macherey-Nagel \#740966), following the manufacturer's instructions. For RNA extraction from tissues, samples were first homogenized in LPB buffer from the NucleoSpin RNA Plus kit using a Buller Blender Gold apparatus (Next Advance) and 0.5 mm zirconium oxide beads. For protein extraction from tissues, samples were sonicated in RIPA buffer (10 mM Tris-HCL pH8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, supplemented with protease and phosphatase inhibitors (Complete Mini and PhosSTOP, Roche)) in 1.5 mL microtubes on ice with five 5-sec pulses at power3 on a Misonix XL-2000 instrument, with a 10-sec timeout on ice between each pulse. The lysates were further incubated with rotation for 30 minutes at 4°C, spun at 11000 x g at 4°C for 15 minutes, and the supernatants transferred to new 1.5 mL microtubes. RNA and protein samples were stored at -80°C until further analysis.

### Western Blotting {#sec5.4.11}

For western blotting, proteins samples were prepared by mixing equal amounts of proteins from cell or tissue lysates with 1X Bolt LDS Sample Buffer (Thermo Fisher \#B0007), 1X Bolt Sample Reducing Agent (Thermo Fisher \#B0009), and incubating at 70°C for 10 minutes with constant motion. The volume of all samples was equilibrated with lysis buffer. Samples were separated on Bolt 4-12% Bis-Tris Plus gels (Thermo Fisher), following the manufacturer's instructions. Proteins were transferred on nitrocellulose (BioTrace NT, PALL Life Sciences) or PVDF (\#03010040001, Roche) membranes in Bolt Transfer Buffer for 1 hour at 30 volts at room temperature. Membranes were blocked with TBST buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.1% Tween-20) containing 5% powdered milk, or 5% bovine serum albumin (BSA), for 1 hour at room temperature. Membranes were then incubated overnight in primary antibody solution, washed three times in TBST, incubated for 1 hour in TBST containing 5% powdered milk or 5% BSA and secondary antibodies and washed three times in TBST. Chemiluminescent detection was performed using Luminata Crescendo Western HRP Substrate (Millipore \#WBLUR0100) and exposing to film (HyBlot CL, Denville Scientific). In some experiments, the western blot membranes were processed with the LI-COR system (LI-COR biotechnology), in which case blocking was performed using the Odyssey Blocking Buffer, and antibody incubations were performed in blocking buffer supplemented with 0.1% Tween-20. Fluorescence detection was performed with an Odyssey CLx instrument (LI-COR). Primary antibodies used were: p-SMAD1/5/8 (Cell Signaling \#13820; 1:1000), p-SMAD1/5/8 (laboratory of Peter ten Dijke, 1:1000 ([@bib69])), SMAD1 (Cell Signaling \#6944, 1:1000), p-SMAD2 (Cell Signaling \#3108, 1:1000), SMAD2 (Cell Signaling \#3103, 1:1000), Id1 (Santa Cruz \#sc-133104, 1:1000), Id2 (Santa Cruz \#sc-398104, 1:1000), Id3 (Santa Cruz \#sc-56712), p-ERK1/2 (Cell Signaling \#9101, 1:1000), ERK1/2 (Cell Signaling \#9102, 1:1000), H3-K27me3 (Millipore \#07-449, 1:1000), total H3 (Abcam \#ab10799, 1:3000), Rb (Cell Signaling \#9309, 1:1000), p-Rb (Cell Signaling \#9308, 1:1000), β-Actin (Sigma \#A2066, 1:5000), α-Tubulin (Sigma \#T6199, 1:5000). Secondary antibodies used were: mouse-HRP (Amersham \#NA9310, 1:5000), Rabbit-HRP (Amersham \#NA934, 1:5000), rabbit-Alexa Fluor 680 (Thermo Fisher \#A21109, 1:5000), mouse-IRDye 800CW (LI-COR \#926-32210, 1:10000). Densitometry analyses were performed using Image J.

### cDNA Synthesis and Quantitative PCR {#sec5.4.12}

cDNA was synthesized using the iScript kit (Bio-Rad), following the manufacturer's instructions. For quantitative PCR, 10 μl reactions comprising 5 μl 2X Power SYBR Green PCR Sample Mix (Applied Biosystems), 3 μl H~2~O, 0.5 μl of each primer (at a 10 μM concentration), and 1 μl cDNA were assembled. Samples were run on a ABI 7900HT Fast Real-Time PCR system (Applied Biosystems) with the following parameters: 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. In all experiments, expression of the genes of interest was normalized to the expression of the housekeeping gene *Rpl19* for mouse samples, and *RPL19* for human samples. Relative gene expression was calculated with the comparative C~t~ method ([@bib63]). All the primers are listed in [Table S4](#mmc3){ref-type="supplementary-material"}.

### RNA-Sequencing and Analysis {#sec5.4.13}

For RNA-sequencing on mouse brainstem samples, total brainstem RNA was processed, and library preparation was performed using the TruSeq Stranded Total RNA kit (Illumina), following the manufacturer's instructions. Sequencing was performed on a Nextseq 500 instrument (Illumina), using a 75-cycle paired-end read protocol and multiplexing, to obtain approximately 40 million reads per sample. Library preparation and sequencing were performed at the Princess Margaret Genomics Centre (Toronto, Canada). The raw 75-basepair paired-end reads from the sequencer were first quality-checked using FASTQC v0.11.5 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and MultiQC v0.8 ([@bib18]) software packages, and then aligned to the *Mus musculus* genome assembly version GRCm38 (mm10) from the Genome Reference Consortium using the STAR aligner v2.5.2b ([@bib15]). The aligned transcripts were quantified using RSEM v1.3.0 ([@bib45]). The RSEM quantification output files were then further processed using in-house R scripts to create a gene-by-sample expression matrix. This matrix of raw RSEM expected counts was then input into the DESeq2 R package v1.20.0 ([@bib47]) for differential expression analysis. Within DESeq2, the default procedure recommended by the package vignette was generally followed. Since the samples were processed and sequenced in two batches, the batch information was included as a feature variable in the linear modeling design formula to account for any batch effects. For statistical analyses, only genes with FPKM\>10 were considered. The baseMean (mean of normalized counts across samples), log~2~FoldChange, and the adjusted p-values obtained using the Benjamini-Hochberg procedure, were used to arrive at the set of top differentially expressed genes. Heatmaps were produced using the pheatmap R package.

Gene Set Enrichment Analysis (GSEA) was performed using the GenePattern platform (Broad Institute, MIT). The "GSEAPreranked" module was used on ranked lists of differentially expressed genes. Gene sets queried were: the "Canonical Pathways" and "Chemical and Genetic Perturbations" subsets of C2 (Curated Gene Sets), C5 (Gene Ontology Gene Sets), and C6 (Oncogenic Signatures).

For RNA sequencing analyses on human tumor samples and normal brain tissue, patients provided informed consent, and ethical approval was obtained from the Hospital for Sick Children Research Ethics Board (\#1000055059). Total RNA was extracted from fresh-frozen tissue samples using the RNeasy mini kit (Qiagen) using the manufacturer's guidelines. Sample quality was confirmed using Bioanalyzer 2100 (Agilent). 34 DIPG and 17 normal brain samples passed quality control. Paired-end, stranded libraries were constructed using TruSeq Stranded Total RNA Library Prep with Ribo-Zero Gold Kit (Illumina) and sequenced on Illumina HiSeq 2500 instruments. After confirming sequencing quality with FastQC v0.11 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), reads were quality trimmed with Trimmomatic v0.35 and aligned to human transcriptome build GRCh37 v75 using RSEM v1.2. Gene expression was quantified as transcripts-per-million. Further information regarding these samples are available from the laboratory of Dr Cynthia Hawkins (Hospital for Sick Children, Toronto, Canada), and the full data set will be published elsewhere.

### Cell Growth and Viability Assays {#sec5.4.14}

For primary glial cell culture proliferation assays, 5000 cells in 200 μl growth medium were seeded in six wells of four 96-wells plates for each genotype or condition. At the indicated time points after plating, 10 μl PrestoBlue reagent (Thermo Fisher) was added to each well, and the cells placed back in a cell culture incubator. Four hours after PrestoBlue addition, absorbance was measured on a FlexStation 3 plate reader (Molecular Devices) under fluorescence settings with an excitation wavelength of 560 nm and an emission wavelength of 590 nm.

For patient-derived DIPG cell lines growth and viability assays, cells were seeded in TSM medium in a volume of 80 μl/well in 96-well plates (SU-DIP-IV: 4000 cells/well; SU-DIPG-VI: 10 000 cells/well; SU-DIPG-XXI: 8000 cells/well; SU-DIPG-XXXVI: 4000 cells/well; HSJD-DIPG-007: 6000 cells/well). The next day, drugs were added at the indicated concentrations, by adding 20 μl of a 5X concentrated stock, in TSM medium, to the cells. Four days later, relative cell growth or viability was assessed using the ATPLite kit (Perkin Elmer), according to the manufacturer's instruction. Luminescence was measured on a FlexStation 3 plate reader (Molecular Devices) with an integration time of 500 ms. Synergy analyses were performed using SynergyFinder ([@bib32]).

### NanoBRET Assays {#sec5.4.15}

HEK-293 cells were transfected in suspension at a density of 2 x 10^5^ cells/ml. For 10 ml of HEK-293 cell suspension, a plasmid mixture of 500 ng of Acvr1-NanoLuc (Promega) and 4.5 μg of transfection carrier DNA (Promega) and 500 μl OPTI-MEM (Thermo Fisher) was prepared. 15 μl of FuGENE HD (Promega) was then added to the plasmid preparation and incubated for 20 minutes at room temperature. 500 μl of the transfection medium was added to 10 ml of HEK-293 cell suspension and the mixture was seeded into a T-75 flask. 24 hours after transfection, cells were trypsinised and re-suspended in phenol red-free OPTI-MEM (Thermo Fisher) at a density of 2 x 10^5^ cells/ml. 17 μl of cell suspension was dispensed into each well of 384-well plate and mixed with 1 μl of 1.3 μM Tracer-6908 (Promega) diluted in 31.25% PEG-400 with 12.5 mM HEPES, pH7.5. Subsequently, 2 μl of E6201 dilutions in phenol red-free OPTI-MEM was added to achieve the concentrations indicated. Cells were agitated at 200rpm for 30 seconds and incubated for 2 hours at 37°C. BRET measurement was done using Intracellular TE Nano-Glo Substrate/Inhibitor reagents (Promega), following the manufacturer's instructions. Donor emission (450nm) and acceptor emission (610nm) were measured simultaneously on PHERAstar FSX microplate reader (BMG Labtech). BRET ratio values were calculated by dividing the acceptor emission by donor emission.

### Reporter Assays {#sec5.4.16}

For reporter assays in primary glial cells, 5 x 10^4^ primary glial cells were seeded in 6-wells plates in 2 mL growth medium per well. The next day, 1.5 x 10^6^ PFU of the appropriate adenoviruses (Ad-GFP; Vector Biolabs \#1060, or Ad-GFP-Cre, Vector Biolabs \#1700) were added to individual wells in 2 mL growth medium. The following day, transduction medium was removed, cells were washed with PBS, and 2 mL fresh growth medium were added in each well. For transfection, a plasmid mixture was prepared containing, for each well: 100 ng of *Renilla*-luciferase plasmid, 1 μg of 6XE2F-Luciferase plasmid (a gift of Dr Kristian Helin, University of Copenhagen), 125 μl OPTI-MEM (Thermo Fisher), and 2 μl P3000 reagent (Thermo Fisher). A mixture containing 125 μl OPTI-MEM and 2 μl Lipofectamine 3000 (Thermo Fisher) for each transfected well was then added to the plasmid preparation, and the samples incubated for 15 minutes at room temperature. 250 μl of the transfection medium was added to the appropriate wells. The next day, the transfection medium was replaced with 2 mL medium without serum. 24 hours later, cells were harvested, lysed and processed for measurement of luciferase activity using the Dual-Luciferase Reporter Assay System (Promega), following the manufacturer's instructions. Luminescence produced by *Renilla* and firefly luciferase activity were measured sequentially on a FlexStation 3 plate reader (Molecular Devices).

For *BRE-Luc* reporter assays in C2C12 and HEK-293 cells, cells were seeded in 24-well plates at a density of 5 x 10^4^ (C2C12) or 1.5 x 10^5^ (HEK-293) cells per well, and transfected with DharmaFECT Duo (Fisher Scientific) or PEI polyethylenimine (Polysciences), following the recommendations of the manufacturers. For ligand-stimulation experiments, cells were transfected with 150 ng *β-gal* control reporter and 300 ng *BRE-Luc* reporter per well. For experiments with receptor expression construct co-transfection, cells were transfected with 90 ng *β-gal* control reporter, 120 ng *BRE-Luc* reporter, and 200 ng receptor expression construct per well. Each transfection mixture was equalized with empty vector when necessary and every experiment was performed in triplicate. The *BRE-Luc* reporter construct ([@bib36]), the expression vectors encoding wild-type and R206H mutant ACVR1 ([@bib74]), and the vectors encoding constitutively active (ca-) ACVR1, BMPR1A, and BMPR1B, have been previously described ([@bib21]). 48 hours after transfection, the cells were incubated with inhibitors and ligands at the concentrations and times indicated. Cells were harvested and lysed, and β-galactosidase and luciferase activity were measured using reporter assay reagents (Promega), following the manufacturer's instructions, on a Victor3 1420 luminometer (Perkin Elmer). Each transfection mixture was equalized with empty vector when necessary.

For *CAGA-Luc* experiments in HEK-293 cells, cells were seeded in 96-well plates at a density of 1 x 10^4^ cells per well. For 100 wells, a plasmid mixture containing 500 ng *Renilla*-luciferase plasmid, 2 μg *CAGA-Luc* plasmid (a gift of Dr Petra Knaus, Free University of Berlin) and 250 μl OPTI-MEM (Thermo Fisher) was prepared. 7.5 μl of FugeneHD (Promega) was then added to the plasmid preparation and incubated for 20 minutes at room temperature. 2.5 μl of the transfection medium was added to each well. 24 hours after transfection, the cells were incubated with 10 ng/ml TGF-β and E6201 simultaneously at the concentrations indicated. 24 hours later, cells were harvested, lysed and processed for measurement of luciferase activity using the Dual-Luciferase Reporter Assay System (Promega), following the manufacturer's instructions. Luminescence produced by firefly and *Renilla* luciferase activity was measured sequentially on a PHERAstar FSX microplate reader (BMG Labtech).

### X-Ray Crystallography {#sec5.4.17}

ACVR1 kinase domain (residues 172--499) and FKBP12 proteins were prepared from Sf9 insect cells and *E coli* strain BL21(DE3)R3-pRARE2, respectively, as described previously ([@bib11]). Proteins were initially purified by nickel affinity chromatography before mixing and subsequent purification by size exclusion chromatography on a Superdex 200 16/600 column. The eluted protein complex was stored in 50 mM HEPES pH 7.5, 300 mM NaCl, 10 mM DTT and the hexahistidine affinity tags cleaved using tobacco etch virus protease. Crystallization was achieved at 4°C using the sitting-drop vapor diffusion method. The ACVR1-FKBP12 complex at 12.5 mg/mL was preincubated with 1 mM E6201 and crystallized using a precipitant containing 0.05 M ammonium sulfate, 30% pentaerythritol ethoxylate 15/4, 0.1 M bis-Tris pH 6.5. Viable crystals were obtained when the protein solution was mixed with the reservoir solution at 2:1 volume ratio. Crystals were cryoprotected with mother liquor plus 25% ethylene glycol prior to vitrification in liquid nitrogen. Diffraction data were collected at the Diamond Light Source beamline I03 using monochromatic radiation at wavelength 0.9763 Å. Data were processed with MOSFLM ([@bib43]) and subsequently scaled using the program AIMLESS from the CCP4 suite ([@bib78]). Initial phases were obtained by molecular replacement using the program PHASER ([@bib50]) and the structure of ACVR1 (PDB [3H9R](pdb:3H9R){#intref0230}) as a search model. The resulting structure solution was refined using Phenix Refine ([@bib1]) and manually rebuilt with COOT ([@bib17]). Appropriate TLS restrained refinement using the tls tensor files calculated from the program TLSMD ([@bib58]) was applied at the final round of refinement. The complete structure was verified for geometric correctness with MolProbity ([@bib13]). Data collection and refinement statistics are shown in [Table S3](#mmc1){ref-type="supplementary-material"}.

### Histology {#sec5.4.18}

Postnatal day 14 and 21 animals were deeply anesthetized using Avertin (250mg/kg, intraperitoneal), and transcardially perfused with PBS, and then with 4% paraformaldehyde (PFA). The brains were dissected, and post-fixed in 4% PFA overnight at 4°C. For postnatal day 7 animals, brains were dissected without perfusion, and fixed in 4% PFA overnight at 4°C. For frozen tissue sections, fixed brains were briefly rinsed in PBS, and cryoprotected by soaking in a 10% sucrose solution for 3 hours at 4°C, and then in a 30% sucrose solution overnight at 4°C. Cryoprotected brains were then embedded in Optimal Cutting Temperature (O.C.T.) compound (VWR), and 8 μm sections were cut on a CryoStar NX70 instrument (Thermo Scientific). O.C.T.-embedded patient tumor samples were obtained from the laboratory of Dr Michelle Monje. The patient characteristics and treatments received are described in ([@bib55]). For paraffin sections, fixed tissue samples were dehydrated, embedded in paraffin using a HistoCore Arcadia H instrument (Leica), and 4.5 μm sections were cut on a RM2255 instrument (Leica). Sections were mounted on +ASSURE®+ frosted slides (Epic Scientific).

For immunohistochemistry, paraffin tissue sections were re-hydrated through a series of xylenes and progressively more diluted ethanol series, ending in water. Endogenous peroxidase activity was neutralized by incubating the section with 3% H~2~O~2~ for 15 min at room temperature. Sections were washed three times in PBS for 5 minutes at room temperature. Antigen retrieval was performed by immersing slides in 10mM sodium citrate, pH 6.0, at over 100°C in a pressurized pressure cooker for 15 minutes. Sections were then washed in PBS for 5 minutes at room temperature, and blocked in PBST (PBS with 0.2% triton) supplemented with with 5% bovine serum albumin (BSA). Antibodies were applied on the sections at the indicated dilutions in PBST-BSA, and incubated overnight at 4°C. Sections were then washed three times in PBS for 5 minutes at room temperature, and secondary antibodies were applied on the sections at the indicated dilutions in PBST-BSA, and incubated for 1 hour at room temperature. Sections were washed three times in PBS for 5 minutes at room temperature, and incubated in ABC reagent mixture (VECTASTAIN Elite ABC HRP Kit, Vector Laboratories) for 30 minutes at room temperature. After a further three washes in PBS for 5 minutes at room temperature, sections were incubated in 100 mM Tris pH7.5 for 5 minutes at room temperature and briefly rinsed in H~2~O. DAB HRP substrate solution (Vector Laboratories), prepared according to the manufacturer's instructions, was applied for 3 minutes, and the sections quickly rinsed in H~2~O. Sections were counterstain with hematoxylin, dehydrated in a graded series of ethanol and xylenes, mounted with TBS (Cole-Parmer) and coversliped. Slides were scanned on a NanoZoomer 2.0 HT instrument.

For immunofluorescence, fixed frozen sections were briefly washed in PBS. Antigen retrieval, blocking and primary antibody incubation were performed as described above. Fluorophore-conjugated antibodies were diluted at the indicated concentrations in PBST-BSA, and applied to the sections for 1 hour at room temperature, protected from light. Sections were then washed three times in PBS for 5 minutes at room temperature with gentle motion, and incubated for 10 minutes at room temperature in 0.5 μg/mL DAPI. After a further three washes in PBS for 5 minutes at room temperature, sections were dehydrated in a graded series of ethanol and xylenes, mounted with Entellan (Sigma), and coverslipped.

Antibodies used were: goat anti-PDGFRA (mouse) (1:100, R&D \#AF1062), rabbit anti-PDGFRA (human) (1:50; Cell Signaling \#5241), rabbit anti-CNPase (1:100, Cell Signaling \#D83E10), rat anti-Ki67 (1:175, Abcam \# ab156956), rabbit anti-GFAP, (1:500, Dako/Agilent \#Z0334), mouse anti-OLIG2 (1:500, Millipore \#MABN50), mouse anti-Nestin (1:100, BD Pharmigen \#556309), biotinylated rabbit anti-goat (1:500, Vector Laboratories \#BA-5000), biotinylated rabbit anti-rat (1:500, Vector Laboratories \# BA-4001), goat anti-Rabbit (1:500, Vector Laboratories \#BA-1000), goat anti-mouse (1:500, Vector Laboratories BA-9200), and Cy5-conjugated donkey anti-rabbit (1:500 Jackson ImmunoResearch \#711-175-152).

To detect endogenous tdTomato fluorescence, fixed frozen sections were briefly washed in PBS, and incubated for 10 minutes at room temperature in 0.5 μg/mL DAPI. Sections were then washed three times with PBS for 5 minutes at room temperature with gentle motion, and mounted with Vectashield medium (Vector Laboratories). Fluorescence images were acquired using a Zeiss AxioImager microscope fitted with a sCMOS camera, and ZEN software.

To quantify tdTomato^+^ cells, images were processed in the ImageJ software (National Institutes of Health). Images were first converted to 16-bit format. For tdTomato fluorescence images, background was substracted using a rolling ball radius of 10 pixels. To restrict the fluorescence to nuclei, the image threshold was then adjusted on a dark background with a 30-70 range. Watershed segmentation was then performed within the binary processing functions of ImageJ to resolve cell doublets. Fluorescence positive cells were then counted using the Analyze Particles function, with a size (in inches^2^) of 0.001 to infinity. The tissue area was measured (in arbitrary units) by tracing the contour of the tissue sections on the images with the polygon selection tool, and then using the "Measure" function. The number of tdTomato^+^ cells was then normalized to the tissue area.

### Chromatin Immunoprecipitation {#sec5.4.19}

Chromatin immunoprecipitation was performed as described ([@bib37]), with some modifications: Chromatin was crosslinked by incubating cells in 1% formaldehyde for 10 minutes at 37°C. Cells were then washed once with PBS+0.5% bovine serum albumin (BSA), and collected in 500 μl PBS containing 1X protease and phosphatase inhibitors (Complete Mini and PhosphoSTOP, Roche ) in 1.5 mL microtubes. Cells were pelleted by centrifugation at 300 x g for 5 minutes at 4°C. Samples were then lyzed in 350 μl Lysis Buffer (50 mM Tris-HCl pH8.1, 10 mM EDTA, 1% SDS, 1X protease and phosphatase inhibitors) by resuspending the cell pellet. Samples were sonicated using a Bioruptor Pico instrument (Diagenode) with 35 cycles of 30 seconds "on" and 30 seconds "off" at 4°C. Samples were then spun at 11 000 x g at 4°C, and the supernatant transferred to new microtubes. Twenty μl of the sample were kept aside as "input" material, and 300 μl added to 1500 μl Dilution Buffer (20 mM Tris-HCl pH8.1, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100) in 2 mL microtubes. For immunoprecipitation, 100 μl of a bead-antibody mixture was added to each sample. These bead-antibody mixtures were prepared as follow: 10 μl Dynabeads A (Thermo Fisher) and 10 μl Dynabeads G per sample (Thermo Fisher) were washed 3 times in 500 μl PBS+0.5%BSA on a magnetic tube holder, incubated with 8 μg/sample H3-K27me3 (Millipore \#07-449), 5 μg/sample H3-K27M (Millipore \#ABE419), 0.5 μg/sample SUZ12 (Cell Signaling \#3737), 4 μg/sample SMAD1 (Cell Signaling \#6944) antibodies, or the equivalent amount of rabbit IgG, in 300 μl PBS+0.5%BSA with rotation of 6 hours at 4°C, washed twice with 500 μl PBS+0.5%BSA on a magnetic tube holder, and resuspended in 100 μl/sample in Dilution Buffer. Samples were rotated overnight at 4°C. The next day, beads were washed three times with 500 μl wash buffer (50 mM HEPES pH7.6, 1 mM EDTA, 0.7% sodium deoxycholate, 1% Nonidet P-40, 0.5 M lithium chloride), and twice with 750 μl 1X TE buffer (10 mM Tris-HCl pH8.0, 1 mM EDTA) on a magnetic tube holder. Beads and "input" samples were then resuspended in 100 μl decrosslinking buffer (1% SDS, 0.1 M sodium bicarbonate), and incubated for 24 hours at 65°C with constant motion. DNA was then isolated using the MinElute purification kit (Qiagen) following the manufacturer's instructions. Samples were assayed by qPCR using the primers listed in [Table S4](#mmc3){ref-type="supplementary-material"}.

### Flow Cytometry and Cell Sorting {#sec5.4.20}

For flow cytometry, cells suspensions were stained as appropriate in FACS buffer (PBS without MgCl~2~ and CaCl~2~, 1% FBS, 2 mM EDTA and 0.05% sodium azide) for 30 minutes on ice, washed twice with 2 mL cold FACS buffer with 5 minutes centrifugation at 4°C between each wash, and resuspended in FACS buffer before cell analysis on a Fortessa (BD Biosciences) instrument.

For lineage tracing and assessment of GFP-expressing DIPG cell lines, cell suspensions were stained with 2 μg/mL DAPI to mark dead cells. For cell sorting, GFP-expressing cells from DIPG cell lines were isolated using an FACSAria cell sorter (BD Biosciences), and collected in FACS buffer. Sorted cells were centrifuged at 300 x g for 5 minutes, resuspended in TSM medium, and plated.

For EdU incorporation measurements, cultured cells were incubated with 10 μM EdU for 2 hours at 37°C in a cell culture incubator, washed in PBS, dissociated as a single-cell suspension in 0.05% trypsin, washed with FACS buffer, and processed for EdU staining using the Click-iT EdU Alexa Fluor 647 Flow Cytometry kit (Thermo Fisher \#C10424), following the manufacturer's instruction. 2 μg/mL DAPI was added to the Click-iT reaction to measure DNA content.

For PDGFRA cell surface staining, brainstem cells were dissociated as described for the preparation of primary brainstem glial cell cultures. The single-cell suspension was stained with 1:100 biotinylated anti-PDGFRA (Thermo Fisher \#13-1401-82), followed by 1:500 Streptavidin-FITC (BD Biosciences \#554060) and 2 μg/mL DAPI to mark dead cells.

For cell cycle assessment, cell suspensions were permeablized by incubating with 500 μl Cytofix/Cytoperm Buffer (BD Biosciences \#554722), washed with 2 mL Perm/Wash Buffer (BD Biosciences \#554723), and stained in Perm/Wash Buffer with 1:100 anti-Ki67-APC (Thermo Fisher \#50-5698-82) and 2 μg/mL DAPI to measure DNA content.

For apoptosis assays, cells were collected in TrypLE and washed with 2 mL FACS buffer. Cells were pelleted by centrifugation at 300 x g for 5 minutes, and the liquid removed by aspiration. Cells were resuspended in 3 mL AnnexinV-binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 2.5 mM CaCl~2~ in PBS), pelleted by centrifugation at 300 x g for 5 minutes, and resuspended in AnnexinV-binding buffer containing 1:50 AnnexinV-FITC (BioLegend \#640906) and 1:50 7-AAD (BioLegend \#420404). Staining was performed for 30 minutes at room temperature, protected from light. Cells were washed twice with 3 mL FACS buffer, and analyzed by flow cytometry. Flow cytometry data were analyzed using FlowJo version 10.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Data were analyzed using t-tests, one- or two-way analysis of variance (ANOVA), Mantel-Cox, Gehan-Breslow-Wilcoxon, or linear regression, followed by multiple-comparisons tests (Bonferonni, Tukey or Sidak) where appropriate, using GraphPad Prism version 7.03. Throughout the manuscript, the following notation was used to indicate statistical significance: ^∗^:*p*\<0.05; ^∗∗^:*p*\<0.01; ^∗∗∗^:*p*\<0.001. All the error bars depict the standard error of the mean (SEM).

Data and Code Availability {#sec5.6}
--------------------------

The mouse RNA-sequencing data has been deposited in Gene Expression Omnibus, under accession number: [GSE142776](ncbi-geo:GSE142776){#intref0235}. The X-ray crystal structure of the ACVR1-FKBP12 complex bound to E6201 has been deposited in the Protein Data Bank, under identification code 6I1S. The human normal brain and DIPG tumor RNA-sequencing data supporting the current study have not been deposited in a public repository because the full analysis of this dataset has not yet been published. The data are available from Dr Cynthia Hawkins (The Hospital for Sick Children, Toronto, Canada) on request.
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